EP2432761A1 - Traitement d'une maladie musculaire caractérisée par une résistance à l'insuline - Google Patents
Traitement d'une maladie musculaire caractérisée par une résistance à l'insulineInfo
- Publication number
- EP2432761A1 EP2432761A1 EP10777262A EP10777262A EP2432761A1 EP 2432761 A1 EP2432761 A1 EP 2432761A1 EP 10777262 A EP10777262 A EP 10777262A EP 10777262 A EP10777262 A EP 10777262A EP 2432761 A1 EP2432761 A1 EP 2432761A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkylene
- alkyl
- heterocycloalkyl
- cycloalkyl
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000029578 Muscle disease Diseases 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 title claims description 96
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract description 18
- 206010022489 Insulin Resistance Diseases 0.000 title abstract description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 253
- 239000003814 drug Substances 0.000 claims abstract description 158
- 229960003105 metformin Drugs 0.000 claims abstract description 147
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims abstract description 145
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 132
- 229940125396 insulin Drugs 0.000 claims abstract description 126
- 102000004877 Insulin Human genes 0.000 claims abstract description 125
- 108090001061 Insulin Proteins 0.000 claims abstract description 125
- 210000003205 muscle Anatomy 0.000 claims abstract description 118
- 230000011664 signaling Effects 0.000 claims abstract description 98
- 239000000203 mixture Substances 0.000 claims abstract description 89
- 230000001419 dependent effect Effects 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 66
- 230000001771 impaired effect Effects 0.000 claims abstract description 63
- 239000003246 corticosteroid Substances 0.000 claims abstract description 61
- 201000006938 muscular dystrophy Diseases 0.000 claims abstract description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 53
- 201000010099 disease Diseases 0.000 claims abstract description 40
- 230000004155 insulin signaling pathway Effects 0.000 claims abstract description 38
- 239000012636 effector Substances 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 86
- 230000000694 effects Effects 0.000 claims description 62
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 61
- 150000001875 compounds Chemical class 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 52
- -1 heterobicycloalkyl Chemical group 0.000 claims description 45
- 125000001072 heteroaryl group Chemical group 0.000 claims description 43
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 42
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 claims description 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 38
- 239000012190 activator Substances 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 32
- 229940002612 prodrug Drugs 0.000 claims description 29
- 239000000651 prodrug Substances 0.000 claims description 29
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 28
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims description 25
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 25
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 24
- 229940123208 Biguanide Drugs 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 125000000304 alkynyl group Chemical group 0.000 claims description 23
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 claims description 22
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 claims description 22
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 21
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 20
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 20
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 20
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 20
- 229960004618 prednisone Drugs 0.000 claims description 20
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 20
- 230000005764 inhibitory process Effects 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 230000003287 optical effect Effects 0.000 claims description 19
- 230000004913 activation Effects 0.000 claims description 18
- 229960005205 prednisolone Drugs 0.000 claims description 18
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 17
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 16
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims description 16
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 15
- 229960001145 deflazacort Drugs 0.000 claims description 15
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 claims description 15
- 102000001708 Protein Isoforms Human genes 0.000 claims description 14
- 108010029485 Protein Isoforms Proteins 0.000 claims description 14
- 230000008901 benefit Effects 0.000 claims description 14
- 150000004283 biguanides Chemical class 0.000 claims description 14
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 238000007911 parenteral administration Methods 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 14
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 13
- 125000005907 alkyl ester group Chemical group 0.000 claims description 13
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 12
- 125000005350 hydroxycycloalkyl group Chemical class 0.000 claims description 12
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 230000037361 pathway Effects 0.000 claims description 10
- 229910020008 S(O) Inorganic materials 0.000 claims description 8
- 238000002648 combination therapy Methods 0.000 claims description 8
- 229960003957 dexamethasone Drugs 0.000 claims description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 claims description 7
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- ORLCYMQZIPSODD-UHFFFAOYSA-N 1-chloro-2-[chloro(2,2,2-trichloroethoxy)phosphoryl]oxybenzene Chemical compound ClC1=CC=CC=C1OP(Cl)(=O)OCC(Cl)(Cl)Cl ORLCYMQZIPSODD-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 claims description 6
- 229940090181 propyl acetate Drugs 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229950010765 pivalate Drugs 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 3
- 238000001361 intraarterial administration Methods 0.000 claims description 3
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 claims 4
- 230000002950 deficient Effects 0.000 abstract description 9
- 102000003746 Insulin Receptor Human genes 0.000 abstract description 6
- 108010001127 Insulin Receptor Proteins 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 4
- 230000003834 intracellular effect Effects 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 68
- 108090000623 proteins and genes Proteins 0.000 description 58
- 210000002027 skeletal muscle Anatomy 0.000 description 53
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 40
- 102000004196 processed proteins & peptides Human genes 0.000 description 40
- 108091008611 Protein Kinase B Proteins 0.000 description 39
- 210000001087 myotubule Anatomy 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 36
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 32
- 230000007170 pathology Effects 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 30
- 229920001184 polypeptide Polymers 0.000 description 27
- 229920002527 Glycogen Polymers 0.000 description 26
- 229940096919 glycogen Drugs 0.000 description 26
- 108091052347 Glucose transporter family Proteins 0.000 description 25
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 24
- 230000026731 phosphorylation Effects 0.000 description 23
- 238000006366 phosphorylation reaction Methods 0.000 description 23
- 229940079593 drug Drugs 0.000 description 21
- 239000000835 fiber Substances 0.000 description 21
- 230000002503 metabolic effect Effects 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 21
- 230000007547 defect Effects 0.000 description 20
- 239000002253 acid Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 108010069091 Dystrophin Proteins 0.000 description 14
- 108091000080 Phosphotransferase Proteins 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 102000020233 phosphotransferase Human genes 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000009826 distribution Methods 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 206010028289 Muscle atrophy Diseases 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 230000003204 osmotic effect Effects 0.000 description 10
- 102000001039 Dystrophin Human genes 0.000 description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- 108010075653 Utrophin Proteins 0.000 description 9
- 102000011856 Utrophin Human genes 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 210000000518 sarcolemma Anatomy 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 102100025682 Dystroglycan 1 Human genes 0.000 description 8
- 108010071885 Dystroglycans Proteins 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 8
- 230000008021 deposition Effects 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 7
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000006308 Sarcoglycans Human genes 0.000 description 7
- 108010083379 Sarcoglycans Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 7
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 201000000585 muscular atrophy Diseases 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 6
- 108010001483 Glycogen Synthase Proteins 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 208000010428 Muscle Weakness Diseases 0.000 description 6
- 206010028372 Muscular weakness Diseases 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003472 antidiabetic agent Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000000021 kinase assay Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 6
- 235000011007 phosphoric acid Nutrition 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- 102100034239 Emerin Human genes 0.000 description 5
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 229960001334 corticosteroids Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 4
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 229940123464 Thiazolidinedione Drugs 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000816 peptidomimetic Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- NOTGFIUVDGNKRI-UUOKFMHZSA-N AICA ribonucleotide Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 NOTGFIUVDGNKRI-UUOKFMHZSA-N 0.000 description 3
- 108700038202 AMP-Activated Protein Kinase Kinases Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004631 Calcineurin Human genes 0.000 description 3
- 108010042955 Calcineurin Proteins 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 108090000620 Dysferlin Proteins 0.000 description 3
- 102100032248 Dysferlin Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229940122199 Insulin secretagogue Drugs 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000029549 Muscle injury Diseases 0.000 description 3
- 208000021642 Muscular disease Diseases 0.000 description 3
- 201000009623 Myopathy Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 201000006793 Walker-Warburg syndrome Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229940125708 antidiabetic agent Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 201000009338 distal myopathy Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229960004580 glibenclamide Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 235000020938 metabolic status Nutrition 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 208000018360 neuromuscular disease Diseases 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000007781 signaling event Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
- CQILNTUUIRCEBL-UHFFFAOYSA-N 2-[4-[[[amino-[[amino(dimethylamino)methylidene]amino]methylidene]amino]methyl]phenyl]ethyl-ethylcarbamic acid Chemical group CCN(C(O)=O)CCC1=CC=C(CN=C(N)N=C(N)N(C)C)C=C1 CQILNTUUIRCEBL-UHFFFAOYSA-N 0.000 description 2
- WRYKUZYKFJPBHU-UHFFFAOYSA-N 2-[4-[[[amino-[[amino(dimethylamino)methylidene]amino]methylidene]amino]methyl]phenyl]octanoic acid Chemical group CCCCCCC(C(O)=O)C1=CC=C(CN=C(N)N=C(N)N(C)C)C=C1 WRYKUZYKFJPBHU-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- KSOQAHBZJSTJQA-UHFFFAOYSA-N 3-[4-[[[amino-[[amino(dimethylamino)methylidene]amino]methylidene]amino]methyl]-3-hydroxyphenyl]-2,2-dimethylpropanoic acid Chemical group CN(C)C(N)=NC(N)=NCC1=CC=C(CC(C)(C)C(O)=O)C=C1O KSOQAHBZJSTJQA-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101100397594 Ancylostoma caninum JNK-1 gene Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010048409 Brain malformation Diseases 0.000 description 2
- 102100033849 CCHC-type zinc finger nucleic acid binding protein Human genes 0.000 description 2
- 102100032539 Calpain-3 Human genes 0.000 description 2
- 102000003904 Caveolin 3 Human genes 0.000 description 2
- 108090000268 Caveolin 3 Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102000004168 Dysferlin Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 2
- 101001030184 Homo sapiens Myotilin Proteins 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 229940122355 Insulin sensitizer Drugs 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 239000012825 JNK inhibitor Substances 0.000 description 2
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- 102100038894 Myotilin Human genes 0.000 description 2
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 108091006300 SLC2A4 Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000005997 bromomethyl group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000012056 cerebral malformation Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000006552 constitutive activation Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000006377 glucose transport Effects 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 238000003674 kinase activity assay Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229950004994 meglitinide Drugs 0.000 description 2
- 239000002395 mineralocorticoid Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000009756 muscle regeneration Effects 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 150000003901 oxalic acid esters Chemical class 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229940080469 phosphocellulose Drugs 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 102000037983 regulatory factors Human genes 0.000 description 2
- 108091008025 regulatory factors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 208000001076 sarcopenia Diseases 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- FESXLDPELYGZCV-UHFFFAOYSA-N tert-butyl n-[4-[[[amino-[(e)-[amino(dimethylamino)methylidene]amino]methylidene]amino]methyl]phenyl]carbamate Chemical group CN(C)C(=N)NC(=N)NCC1=CC=C(NC(=O)OC(C)(C)C)C=C1 FESXLDPELYGZCV-UHFFFAOYSA-N 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 150000003628 tricarboxylic acids Chemical class 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- HCHFRAXBELVCGG-JYFOCSDGSA-N (2z,3z)-2,3-bis[(4-methoxyphenyl)methylidene]butanedinitrile Chemical compound C1=CC(OC)=CC=C1\C=C(/C#N)\C(\C#N)=C\C1=CC=C(OC)C=C1 HCHFRAXBELVCGG-JYFOCSDGSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- GBCQLGDTLMHVHU-UHFFFAOYSA-N 2,3,4,4a,5,6,7,8,9,9a-decahydro-1h-benzo[7]annulene Chemical compound C1CCCCC2CCCCC21 GBCQLGDTLMHVHU-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- ZINGTSKJTAZDTM-UHFFFAOYSA-N 3-[[amino-[(e)-[amino(dimethylamino)methylidene]amino]methylidene]amino]propyl acetate Chemical compound CN(C)C(\N)=N\C(N)=NCCCOC(C)=O ZINGTSKJTAZDTM-UHFFFAOYSA-N 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- KPOHQIPNNIMWRL-UHFFFAOYSA-N 3-chloropropyl acetate Chemical compound CC(=O)OCCCCl KPOHQIPNNIMWRL-UHFFFAOYSA-N 0.000 description 1
- QFRLDZGQEZCCJZ-UHFFFAOYSA-N 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(5-nitro-2-thiazolyl)thio]-1H-1,2,4-triazol-5-one Chemical compound S1C([N+](=O)[O-])=CN=C1SC1=NNC(=O)N1C1=CC=C(OCCO2)C2=C1 QFRLDZGQEZCCJZ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- HCEQQASHRRPQFE-UHFFFAOYSA-N 5-chloro-n-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide;3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N.COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 HCEQQASHRRPQFE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102400000310 Alpha-dystroglycan Human genes 0.000 description 1
- 101800000379 Alpha-dystroglycan Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102100022291 C-Jun-amino-terminal kinase-interacting protein 1 Human genes 0.000 description 1
- 101710105206 C-Jun-amino-terminal kinase-interacting protein 1 Proteins 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 101710116319 CCHC-type zinc finger nucleic acid binding protein Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108030001375 Calpain-3 Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000035902 Critical illness myopathy Diseases 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102100021790 Delta-sarcoglycan Human genes 0.000 description 1
- 108050006847 Delta-sarcoglycan Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- HCHFRAXBELVCGG-UHFFFAOYSA-N Emerin Natural products C1=CC(OC)=CC=C1C=C(C#N)C(C#N)=CC1=CC=C(OC)C=C1 HCHFRAXBELVCGG-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100021792 Gamma-sarcoglycan Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 1
- 101100023496 Homo sapiens MAPK8 gene Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 1
- 101000594629 Homo sapiens Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 Proteins 0.000 description 1
- 101000666657 Homo sapiens Rho-related GTP-binding protein RhoQ Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 229940118135 JNK inhibitor Drugs 0.000 description 1
- 229940122348 JNK1 inhibitor Drugs 0.000 description 1
- 206010048911 Lissencephaly Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 201000001087 Miyoshi muscular dystrophy Diseases 0.000 description 1
- 208000009376 Miyoshi myopathy Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000004472 Myostatin Human genes 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150037263 PIP2 gene Proteins 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 101710139643 Polyadenylate-binding protein 1 Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 102100026531 Prelamin-A/C Human genes 0.000 description 1
- 208000028872 Progressive muscular dystrophy Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100036226 Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 102100038339 Rho-related GTP-binding protein RhoQ Human genes 0.000 description 1
- 102100031774 Ribitol 5-phosphate transferase FKRP Human genes 0.000 description 1
- 101710087595 Ribitol 5-phosphate transferase FKRP Proteins 0.000 description 1
- 102100031754 Ribitol-5-phosphate transferase FKTN Human genes 0.000 description 1
- 101710087566 Ribitol-5-phosphate transferase FKTN Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000008144 Rigid spine syndrome Diseases 0.000 description 1
- 101150097537 Ryr1 gene Proteins 0.000 description 1
- 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 1
- 101150110386 SLC2A4 gene Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
- 101710184528 Scaffolding protein Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 101150045355 akt1 gene Proteins 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000020538 atrophic muscular disease Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000025261 autosomal dominant disease Diseases 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical class [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 108010044481 calcineurin phosphatase Proteins 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 101150062912 cct3 gene Proteins 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 201000007303 central core myopathy Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006743 cytoplasmic accumulation Effects 0.000 description 1
- 210000003674 cytoplasmic vesicle Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- HWSUUGHIDOOOOJ-UHFFFAOYSA-N dioxaphosphinane Chemical compound C1COOPC1 HWSUUGHIDOOOOJ-UHFFFAOYSA-N 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229940125542 dual agonist Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 108010056197 emerin Proteins 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229950004153 gliamilide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940112611 glucovance Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 102000057878 human DMD Human genes 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 208000014817 lissencephaly spectrum disease Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 208000011042 muscle-eye-brain disease Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- MQQJZPWSYVPWPF-QYZOEREBSA-N n-[2-[1-[[(1r,4r,5r)-5-bicyclo[2.2.1]hept-2-enyl]methylcarbamoylsulfamoyl]piperidin-4-yl]ethyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=CC=C1C(=O)NCCC1CCN(S(=O)(=O)NC(=O)NC[C@H]2[C@@H]3C[C@@H](C=C3)C2)CC1 MQQJZPWSYVPWPF-QYZOEREBSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000001696 pelvic girdle Anatomy 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000011340 peptidyl-tyrosine autophosphorylation Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000008375 physiological alteration Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 229960005385 proguanil Drugs 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108010065251 protein kinase modulator Proteins 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000029964 regulation of glucose metabolic process Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000006956 rigid spine muscular dystrophy 1 Diseases 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 208000034373 type A muscular dystrophy-dystroglycanopathy Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/08—Sulfenic acids; Derivatives thereof
- C07C313/18—Sulfenamides
- C07C313/26—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C313/30—Y being a hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657154—Cyclic esteramides of oxyacids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present disclosure relates generally to therapeutic agents, compositions and methods for treating muscle diseases and conditions characterized by impaired insulin-dependent signaling in muscle tissue, in essence, a form of insulin resistance.
- Muscular dystrophy refers to a group of hereditary, progressive, degenerative disorders characterized by progressive muscle weakness, defects in muscle proteins, and the destruction of muscle fibers and tissue over time. In many cases, the histological picture shows variation in fiber size, muscle cell necrosis and regeneration, and often proliferation of connective and adipose tissue. The diseases primarily target the skeletal or voluntary muscles. However, muscles of the heart and other involuntary muscles are also affected in certain forms of muscular dystrophy.
- muscular dystrophy There are several forms of muscular dystrophy, which differ in their age of onset, penetrance, severity, and pattern of muscles affected.
- Known forms of muscular dystrophy include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Limb-Girdle muscular dystrophies, myotonic dystrophy (Steinert's disease), Emery-Dreifuss muscular dystrophy, Landouzy-Dejerine muscular dystrophy, facioscapulohumeral muscular dystrophy (FSH), von Graefe-Fuchs muscular dystrophy, oculopharyngeal muscular dystrophy (OPMD), distal muscular dystrophy, and congenital muscular dystrophies.
- DMD Duchenne muscular dystrophy
- BMD Becker muscular dystrophy
- Limb-Girdle muscular dystrophies myotonic dystrophy (Steinert's disease)
- Emery-Dreifuss muscular dystrophy Landouzy-Dejer
- DMD Duchenne Muscular Dystrophy
- DMD originates from mutations in the dystrophin gene located on the X chromosome (Xp21), leading to loss of dystrophin protein with attendant muscle fiber destruction.
- Xp21 X chromosome
- the discovery of the dystrophin gene and the subsequent characterization of the protein product have established dystrophin as an integral sarcolemmal protein, linking the muscle sarcomere and cytoskeleton to the surrounding extracellular matrix.
- the localization of dystrophin is synonymous with maintaining muscle integrity and its absence (as evidenced in DMD) leads to membrane fragility, contraction induced myofiber damage, and death (Petrof et al. 1993).
- Becker type muscular dystrophy also known as Benign pseudohypertrophic muscular dystrophy is an X-linked recessive inherited disorder characterized by slowly progressive muscle weakness of the legs and pelvis, which is also caused by mutations in the dystrophin gene, has onset in adolescence or adulthood with a less severe course of progression.
- BMD is related to Duchenne Muscular Dystrophy in that both result from a mutation in the dystrophin gene, but in DMD no functional dystrophin is produced making DMD much more severe than BMD. Both DMD and BMD have traditionally been called "X-linked" recessive diseases (Freund et al., 2007).
- the limb girdle muscular dystrophies all show a similar distribution of muscle weakness, affecting both upper arms and legs. Many forms of limb girdle muscular dystrophy have been identified, showing different patterns of inheritance: autosomal recessive (designated LGMD1) or autosomal dominant (LGMD2).
- LGMD1 autosomal recessive
- LGMD2 autosomal dominant
- an individual receives two copies of the defective gene, one from each parent.
- the disorder can occur in either sex when an individual inherits a single defective gene from either parent.
- the recessive limb girdle muscular dystrophies are more frequent than the dominant forms, and may be more severe.
- Limb girdle muscular dystrophy can have a childhood onset, although more often symptoms appear in adolescence or young adulthood.
- the dominant limb girdle muscular dystrophies usually show adult onset.
- Some of the recessive forms have been associated with defects in proteins that make up the dystrophin-glycoprotein complex. Mutations in one component of the dystrophin- glycoprotein complex, the sarcoglycans, can lead to the forms of limb girdle muscular dystrophy known as LGMD2C, 2D, 2E, and 2F.
- LGMD1 C Defects in caveolin 3, a protein that associates with the dystrophin-glycoprotein complex, lead to LGMD1 C, while mutations in dysferlin, a protein that is thought to interact with caveolin 3, cause LGMD2B. Mutations in genes not related to the dystrophin-glycoprotein complex are implicated in other forms of limb girdle muscular dystrophy. For example, mutations in the enzymatic protein calpain 3 lead to LGMD2A (Guglieri M. et al., 2008). [0008] Myotonic dystrophy is the most common form of muscular dystrophy.
- Type 1 myotonic dystrophy (DM1) is caused by expansion of a CTG triplet repeat in an untranslated region of the dystrophia myotonica protein kinase gene (DMPK) on chromosome 19, while type 2 (DM2) is caused by expansion of a CCTG repeat in the first intron of the zinc finger protein-9 gene (ZNF9) on chromosome 3.
- DM1 dystrophia myotonica protein kinase gene
- ZNF9 zinc finger protein-9 gene
- DM1 myotonic dystrophies
- DM1 also has congenital and childhood onset forms; these early appearing forms of the disease differ mechanistically from the adult form only in exhibiting larger CTG repeats that, in turn, trigger earlier appearance of symptoms.
- Those patients that survive early onset DM1 frequently exhibit morbidity and mortality in the third and fourth decades relating to cardiopulmonary involvement (Liquori CL. et al., 2001 ; Cho DH. et al., 2007).
- Facioscapulohumeral muscular dystrophy a dominantly inherited disorder, is the third most common dystrophy after Duchenne and myotonic muscular dystrophy.
- FSHD is an autosomal dominant progressive degenerative disease that initially affects the muscles of the face (facio), shoulders (scapulo), and upper arms (humeral), followed by the muscles of the feet, pelvic girdle, and abdomen. Affected individuals may also suffer from hearing loss. Onset and progression of the disease is variable and often the weakness is asymmetrical in affected individuals. Life expectancy is typically within normal range, but the disease can lead to severe disability. Nearly all cases are associated with deletions of tandem repeats, termed D4Z4, in a distal region of chromosome 4 (4q35) (Tawil R., 2008).
- the congenital muscular dystrophies are a heterogeneous class of disorders, and include several disorders with a range of symptoms. Muscle degeneration can be mild or severe, and may be restricted to skeletal muscle, or paired with effects on the brain and other organs. Defects in the protein merosin are responsible for about half of the cases in the U.S. Mutations in one of the integrin proteins gives rise to another form of congenital muscular dystrophy. Defects in the proteins called fukutin and fukutin- related protein cause the most common forms of congenital muscular dystrophy found in Japan. All of these proteins are thought to have some relationship to the dystrophin- glycoprotein complex.
- congenital muscular dystrophy including Fukuyama muscular dystrophy, muscle-eye brain disease, and Walker- Warburg syndrome are due to defective glycosylation of one of the proteins in the dystrophin-glycoprotein complex (alpha-dystroglycan) and show severe brain malformations, such as lissencephaly (a "cobblestone” appearance to part of the brain) and hydrocephalus (an excessive accumulation of fluid in the brain).
- Other forms, including the merosin-absent form and rigid spine syndrome do not have major brain malformations associated with the disease.
- the molecular basis for many forms of congenital muscular dystrophy remains unknown (Sewry CA., 2008).
- Emery-Dreifuss muscular dystrophy is characterized by weakness in the shoulder girdle and lower legs, as well as the development of contractures in regions of the body, particularly the elbows, Achilles tendons, and neck. Defects in proteins that make up the nucleus, including emerin, and lamin A/C, are implicated in the disorder.
- the mdx mouse model is a well-accepted animal model of human DMD.
- the mdx mouse carries a premature stop codon in exon 23 of the dystrophin gene and exhibits no detectable levels of dystrophin in muscle tissue.
- the progression of disease pathology in the dystrophic mdx mouse has been associated with constitutive activation of the MAP kinase, JNK1 (Kolodziejczyk et al. 2001), a ubiquitous signaling molecule. Once activated, JNK1 can phosphorylate the transcription factor NF-ATd , leading to cytoplasmic accumulation and loss of NF-ATd function.
- JNK1 scaffolding protein JIP-1 Direct inhibition of JNK1 in dystrophic muscle, by overexpression of the JNK1 scaffolding protein JIP-1 , was shown to reduce damage associated with typical disease progression (Kolodziejczyk et al. 2001).
- the present inventors have previously shown that the glucocorticoid, deflazacort, attenuates DMD pathology by circumventing and limiting the deleterious effects of JNK1 (St-Pierre et al. 2004).
- Deflazacort did not directly inhibit JNK1 , rather the beneficial effects of this compound appear to originate from increasing the activity of the calcineurin phosphatase.
- calcineurin then dephosphorylates NF-ATd , restoring NF- ATd nuclear localization and transcriptional function (St-Pierre et al. 2004).
- Other groups have now demonstrated that increased calcineurin activity alleviates dystrophic muscle pathology (Chakkalakal et al. 2004; Chakkalakal et al. 2006; Stupka et al. 2006; Stupka et al. 2008).
- DMD muscular dystrophy
- Current treatments for DMD consist primarily of supportive care, including physical rehabilitation with braces, wheelchairs and ventilators, which can temporarily slow progression of disease and are essential in preventing complications and improving quality of life.
- Corticosteroids e.g., prednisone, prednisolone and deflazacort
- prednisone, prednisolone and deflazacort are the only drugs that have been extensively studied as a pharmacologic therapy for DMD.
- Prednisone is a synthetic corticosteroid drug that is usually taken orally, but can also be delivered by intramuscular injection. It is the corticosteroid most commonly prescribed for the treatment of DMD in North America. As with other steroid drugs, it is used to treat a number of different diseases and conditions. Prednisone is a prodrug that is converted by the liver into prednisolone, which is the active steroid. Prednisone can be effective in delaying the onset of symptoms of DMD, although the mechanism for the delay of symptoms is unknown.
- Gene therapy offers future hope in the treatment of inherited single gene disorders, such as DMD, through targeting genetic defects and helping restore the defective protein. Indeed, it is widely believed that in the future, gene therapy could provide the cure for disorders such as DMD because it targets the disorder directly, whereas most other forms of treatment target only the symptoms of disease. However, at the present time, such therapy remains a distant reality and there is an immediate need for new and improved treatments. [0020] It is, therefore, desirable to provide new compositions and methods for treating muscle diseases and conditions, including but not limited to, muscular dystrophy.
- a therapeutic agent for treating or preventing a muscle disease or condition characterized by impaired insulin-dependent signaling in muscle tissue is an activator of the insulin signaling pathway.
- the therapeutic agent exerts effects downstream of IRS-1 in the pathway.
- the therapeutic agent may exert effects either directly or indirectly on effector molecules downstream of IRS-1 in the insulin signaling pathway.
- the therapeutic agent may, for example, exert one or more of the following effects: inhibition of JNK1 ; activation of AMPK; activation of AKT; or inhibition of GSK3 ⁇ .
- the therapeutic agent inhibits JNK1.
- the therapeutic agent activates AMPK.
- the therapeutic agent activates AKT.
- the therapeutic agent inhibits GSK3 ⁇ .
- the therapeutic agent is selected from the group consisting of biguanides, AMPK activators, and analogues and derivatives thereof.
- the therapeutic agent is a biguanide, such as, metformin or an analogue or derivative thereof.
- the therapeutic agent is metformin.
- the therapeutic agent is a biguanide derivative.
- the biguanide derivative may, for example, be a prodrug.
- the prodrug is a compound of Formula II:
- R1 and R2 are independently selected from the group consisting of H, alkyl, alkoxy, haloalkyl, hydroxyalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, alkylene- O-alkyl, alkylene-O-cycloalkyl, alkylene-O-heterocycloalkyl, alkylene-O-alkylene- cycloalkyl, alkylene-O-alkylene-heterocycloalkyl, C(O)-alkyl, C(OO)-alkyl, C(0)-cycloalkyl, C(00)-cycloalkyl, C(0)-heterocycloalkyl, S(0)2-heterocycloalkyl, alkylene-O-aryl, alkylene
- R3 is selected from the group consisting of C1- to C8-lower alkyl, C1- to C8-lower alkoxy, C1- to C8-lower alkyl-ester, cycloalkyl, heterocycloalkyl, bicycloalkyl, heterobicycloalkyl, aryl, heteroaryl, optionally-substituted aryl, optionally-substituted hetero-aryl; hydroxyalkyl, hydroxycycloalkyl, hydroxy-heterocycloalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, alkylaryl, alkylheteroaryl, alkylene-O-alkyl, alkylene-O-cycloalkyl, alkylene-O-heterocycloalkyl, alkylene-O-alkylene- cycloalky
- the compound of Formula Il is a compound of
- R1 and R2 are independently selected from the group consisting of H, alkyl, alkoxy, haloalkyl, hydroxyalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, alkylene- O-alkyl, alkylene-O-cycloalkyl, alkylene-O-heterocycloalkyl, alkylene-O-alkylene- cycloalkyl, alkylene-O-alkylene-heterocycloalkyl, C(O)-alkyl, C(OO)-alkyl, C(0)-cycloalkyl, C(00)-cycloalkyl, C(0)-heterocycloalkyl, S(0)2-heterocycloalkyl, alkylene-O-aryl, alkylene
- R4 is selected from the group consisting of H, hydroxy, halogen, cyano, nitro, carboxylic ester, carboxylic acid, carboxylic amide, C1- to C8-lower alkyl, C1- to C8-lower alkoxy, C1- to C8-lower alkyl-ester, cycloalkyl, heterocycloalkyl, bicycloalkyl, heterobicycloalkyl, aryl, heteroaryl, optionally-substituted aryl, optionally-substituted hetero-aryl; hydroxyalkyl, hydroxycycloalkyl, hydroxy-heterocycloalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, alkylaryl, alkylheteroaryl, alkylene-O-alkyl, alkylene-O-cycloal
- R5 to R8 are independently selected from the group consisting of C1- to C8-lower alkyl, C1- to C8-lower alkoxy, C1- to C8-lower alkyl-ester, halo-alkyl-ester cycloalkyl, heterocycloalkyl, bicycloalkyl, heterobicycloalkyl, aryl, heteroaryl, optionally-substituted aryl, optionally-substituted hetero-aryl; hydroxyalkyl, hydroxycycloalkyl, hydroxy- heterocycloalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, alkylaryl, alkylheteroaryl, alkylene-O-alkyl, alkylene-O-cycloalkyl, alkylene-O-heterocycloalkyl, alkylene
- n is selected from 1 to 4 and m from 0 to 2.
- R1 and R2 are independently selected from the group consisting of alkyl, cycloalkyl and heterocycloalkyl.
- R5, R6, R7 and R8 are independently selected from the group consisting of C1- to C8-lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; and/or a pharmaceutically-acceptable salt, hydrate, solvate, isoform, tautomer, optical isomer, or combination thereof.
- the therapeutic agent is N1 ,N1-Dimethyl-S- cyclohexyl-N4-thiohydroxylbiguanidine.
- the therapeutic agent is N1 ,N1-Dimethyl-S-phenyl-N4-thiohydroxylbiguanidine.
- the therapeutic agent is tert-Butyl 4-[(3-(N,N-Dimethylcarbamimidoyl)guanidino)methyl]phenyl -carbamate.
- the therapeutic agent is 4- ⁇ [3-(N,N- Dimethylcarbamimidoyl)guanidino]methyl ⁇ phenyl -octanoate.
- the therapeutic agent is 4- ⁇ [3-(N,N-Dimethylcarbamimidoyl)guanidino]methyl ⁇ phenyl- diethylcarbamate.
- the therapeutic agent is 4-[(3-(N, N- Dimethylcarbamimidoyl)guanidino)methyl]-3-hydroxyphenyl-pivalate. In some embodiments, the therapeutic agent is 3-[3-(N, N-
- the therapeutic agent is [(N',N'-Dimethylguanidino)iminomethyl]carbamic acid benzyl-ester. In some embodiments, the therapeutic agent is [(N',N'-Dimethylguanidino)iminomethyl]carbamic acid 2,2,2-trichloroethyl -ester. In some embodiments, the therapeutic agent is [(N1 ,N1- Dimethylcarbamimidoyl)guanidino]-4-phenyl-1 ,3,2-dioxaphosphoramidate.
- the therapeutic agent is a pharmaceutically-acceptable salt, hydrate, solvate, isoform, tautomer, optical isomer, or combination thereof, of any of the above compounds.
- the compositions disclosed herein comprise at least one pharmaceutically acceptable carrier and/or excipient.
- the disease or condition characterized by impaired insulin-dependent signaling in muscle tissue is a muscular dystrophy.
- the muscular dystrophy is Duchenne muscular dystrophy, Becker muscular dystrophy, a limb-girdle muscular dystrophy, or a related dystrophy.
- the muscular dystrophy is Duchenne muscular dystrophy.
- compositions disclosed herein further comprise a corticosteroid, for example, prednisone, prednisolone, deflazacort, or a combination thereof.
- corticosteroid is prednisone.
- the corticosteroid is prednisolone.
- the corticosteroid is deflazacort.
- a composition as disclosed herein comprises metformin and a corticosteroid.
- a composition as disclosed herein comprises metformin and a prednisone.
- a composition as disclosed herein comprises metformin and a prednisolone.
- a composition as disclosed herein comprises metformin and a deflazacort.
- a biguanide derivative selected from the group consisting of:
- a method of treating or preventing a muscle disease or condition characterized by impaired insulin-dependent signaling in muscle tissue comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a therapeutic agent as defined herein.
- a subject in need thereof may be a subject that has, is suspected of having, or is at risk of developing a muscle disease or condition characterized by impaired insulin-dependent signaling.
- the therapeutic agent is metformin or an analogue or derivative thereof.
- the therapeutic agent is metformin.
- the method further comprises administering a corticosteroid to the subject.
- the corticosteroid is prednisone, prednisolone, deflazacort, dexamethasone or a combination thereof.
- the corticosteroid is prednisone.
- the corticosteroid is prednisolone.
- the corticosteroid is deflazacort.
- the corticosteroid is dexamethasone.
- the corticosteroid may be administered to the subject together with or separately from the therapeutic agent.
- the corticosteroid may be administered to the subject prior to, concurrently with, or subsequent to the therapeutic agent.
- the corticosteroid is administered to the subject prior to the therapeutic agent.
- corticosteroid is administered to the subject concurrently with the therapeutic agent.
- the corticosteroid is administered to the subject subsequent to the therapeutic agent.
- the therapeutic agent may be administered by any suitable route of administration, for example, local or systemic routes of administration.
- the therapeutic agent is administered orally or parenterally.
- the therapeutic agent is administered orally.
- the therapeutic agent is administered parenterally.
- the parenteral administration is intramuscular, subcutaneous, intravenous, or intraarterial. In some embodiments, the parenteral administration is intramuscular. In some embodiments, the parenteral administration is intravenous. In some embodiments, the parenteral administration is intraarterial.
- a method of treating Duchenne muscular dystrophy comprising administering to a patient a therapeutically effective amount of metformin.
- the method further comprises administration of a corticosteroid.
- the metformin and the corticosteroid are administered together.
- the metformin and the corticosteroid are administered separately.
- a kit or commercial package for the treatment of muscular dystrophy comprising metformin and instructions for use in the treatment of muscular dystrophy.
- kits or commercial package for the treatment of muscular dystrophy comprising, metformin and a corticosteroid, together with instructions for their administration in a combination therapy.
- compositions as described herein for the treatment or prevention of a muscle disease or condition characterized by impaired insulin dependent signaling.
- composition of a composition as described herein for the manufacture of a medicament for the treatment or prevention of a muscle disease or condition characterized by impaired insulin dependent signaling.
- composition as described herein for the treatment or prevention of a muscle disease or condition characterized by impaired insulin dependent signaling.
- metformin or an analogue or derivative thereof for the treatment or prevention of a muscle disease or condition characterized by impaired insulin dependent signaling.
- a combination of metformin or an analogue or derivative thereof and a corticosteroid for the treatment or prevention of a muscle disease or condition characterized by impaired insulin dependent signaling.
- a method of determining whether a patient suffering from a muscle disease or condition would benefit from treatment with an activator of the insulin signaling pathway comprising: obtaining a muscle-derived biological sample from the subject; and testing the sample for impaired insulin dependent signaling, wherein the identification of impaired insulin dependent signaling is indicative that the patient would benefit from treatment with an activator of the insulin signaling pathway.
- the method further comprises the step of administering an activator of the insulin signaling pathway to the patient.
- the activator of the insulin signaling pathway is metformin or a derivative thereof.
- Figure 1 is a Schematic Representation of the Insulin-Dependent
- Insulin binds to its receptor (IR) leading to autophosphorylation, catalyzing the phosphorylation of insulin receptor substrates (IRS).
- IRS insulin receptor substrates
- PI3K phosphoinositide 3-kinase
- PIP2 phosphoinositide 3-kinase
- PIP3 phosphatidylinositol3
- AKT glycogen synthase kinase 3
- GLUT4 glycogen synthase kinase 3
- Glycogen synthase is a major substrate of GSK3 and catalyses the final step in glycogen synthesis. Phosphorylation of glycogen synthase by GSK3 inhibits glycogen synthesis; therefore the inactivation of GSK3 by AKT promotes glucose storage as glycogen. Additionally, autophosphorylation of the IR also results in activation of the CpI-CAP-APS complex leading to formation of Crkll-C3G complex which stimulates TC10 activity. These pathways act to coordinate the regulation of vesicle trafficking, protein synthesis and gene expression, which results in the regulation of glucose, lipid and protein metabolism.
- FIG. 1 illustrates that IRS-1 Serine Phosphorylation is Increased in
- FIG. 3 illustrates that normal AKT phosphorylation and GSK-3 ⁇ activity are altered in Dystrophic Skeletal Muscle.
- AKT was immunoprecipitated from skeletal muscles (TA and DIA) wild-type (WT) and MDX mice. AKT kinase assay was preformed using AKT substrate peptide and [ ⁇ -32P]ATP. Kinase reaction was dotted on p81 paper and radioactivity was measured by scintillation counter (mean +SE; n > 3 *p ⁇ 0.05).
- Active GSK-3 ⁇ was immunoprecipitated and GSK-3 ⁇ kinase assay was preformed using GSK-3 ⁇ peptide substrate and [ ⁇ -32P]ATP. Kinase reaction was dotted on p81 paper and radioactivity was measured by scintillation counter (mean +SE; n > 3 *p ⁇ 0.05).
- FIG. 4 illustrates that Metformin Treatment Restores Normal AKT phosphorylation and GSK-3 ⁇ inactivity in Dystrophic Skeletal Muscle.
- AKT was immunoprecipitated from the skeletal muscle (TA and DIA) from MDX-saline (MS) and M DX- metformin treated) mice.
- AKT kinase assay was preformed using AKT substrate peptide and [v- 32P]ATP. Kinase reaction was dotted on p81 paper and radioactivity was measured by scintillation counter (mean+SE; n > 3 *p ⁇ 0.05).
- Figure 5 illustrates that Metformin Treatment Restores GLUT4
- Metformin administration increased protein levels of utrophin, ⁇ -dystroglycan, ⁇ -sarcoglycan and utrophin in the gastrocnemius compared to Saline-treated mdx controls (Fig. 9A). Metformin treatment led to a notable increase in sarcolemmal distribution of both ⁇ -dystroglycan and ⁇ -sarcoglycan along the sarcolemma in mdx-myofibers (Fig. 9B and C). lmmunohistochemical analysis revealed that metformin administration led to a robust increase in utrophin along the extrasynaptic sarcolemma (Fig. 9D).
- FIG. 10 illustrates that Metformin Treatments decreases sarcolemmal damage in dystrophic skeletal muscle.
- A Macroscopic evidence of EBD infiltration in TA and gastrocnemius (G) muscles from mdx mice treated with saline or metformin for 28 days.
- B Uptake of EBD shown by red fluorescence on transverse sections of gastrocnemius muscle fibres. White arrows indicate muscle fibers that have taken up significant EBD, which fibres appear lighter shade of gray than surrounding fibers in figure. Sarcolemma is visible defining the perimeters of the fibers (scale bar, 20um).
- C Quantification of EBD-positive fibers.
- FIG. 11 illustrates the Metformin treated mdx-mice display improved running endurance compared to saline-treated mdx-mice.
- the present disclosure provides therapeutic agents, compositions and methods for treating muscle diseases or conditions characterized by metabolic disturbance in muscle tissue, in particular, impaired insulin-dependent signaling.
- the term “impaired insulin-dependent signaling” refers generally to a form of insulin resistance wherein cells become less sensitive to the effects of insulin. More particularly, as used herein, “impaired insulin-dependent signaling” refers to an impairment that results in elevated phosphorylation of the IRS-1 at serine 307 leading to inhibition in insulin signaling. The term “defective” insulin signaling is also used herein.
- the muscle disease or condition characterized by impaired insulin-dependent signaling is one or more of a muscle degenerative disease, a myopathy, or a disease or condition characterized by muscle wasting or atrophy. A skilled person will appreciate that other muscle diseases and conditions besides those listed above may be tested and found to be characterized by impaired insulin-dependent signaling. Such muscle diseases and conditions are considered within the scope of the present disclosure.
- the muscle disease or condition characterized by impaired insulin-dependent signaling is a muscle degenerative disease, including but not limited to a muscular dystrophy.
- Muscular dystrophies include, but are not limited to,
- Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, limb-girdle muscular dystrophies, myotonic dystrophy (also known as Steinert's disease), facioscapulohumeral muscular dystrophy, congenital muscular dystrophies, oculopharyngeal muscular dystrophy, distal muscular dystrophies and Emery-Dreifuss muscular dystrophy.
- DMD Duchenne muscular dystrophy
- Becker muscular dystrophy limb-girdle muscular dystrophies
- myotonic dystrophy also known as Steinert's disease
- facioscapulohumeral muscular dystrophy also known as Steinert's disease
- facioscapulohumeral muscular dystrophy congenital muscular dystrophies
- oculopharyngeal muscular dystrophy distal muscular dystrophies
- Emery-Dreifuss muscular dystrophy e.g., Hoffman et al., N. Engl. J. Med., 318.1
- the muscular dystrophy is Duchenne muscular dystrophy, Becker muscular dystrophy, a Limb-Girdle muscular dystrophy, myotonic dystrophy or a related dystrophy characterized by impaired insulin-dependent signaling.
- the muscular dystrophy originates from disruptions in the dystrophin- dystroglycan complex.
- the muscular dystrophy is Duchenne muscular dystrophy (DMD).
- the muscular dystrophy is Becker muscular dystrophy (BMD).
- the muscular dystrophy is a Limb-Girdle muscular dystrophy.
- the muscular dystrophy is myotonic dystrophy.
- the muscular dystrophy is a congenital muscular dystrophy characterized by impaired insulin dependent signaling.
- the muscle disease or condition characterized by impaired insulin-dependent signaling is a disease or condition characterized by muscle wasting or atrophy, for example, a disuse atrophy, for example, sarcopenia or intensive care atrophy.
- the disease or condition is a myopathy.
- the disease or condition is a critical illness myopathy, which may, for example, be brought about from bone marrow transplant, sepsis, multi-organ failure, or prolonged mechanical ventilation. This is referred to in the literature as CINMA or critical illness neuromuscular abnormalities and it affects approximately 50% of all ICU patients.
- therapeutic agents for treating and/or preventing a disease or condition characterized by impaired insulin dependent signaling.
- the therapeutic agent targets the underlying signaling defect.
- a "therapeutic agent” is a molecule or group of molecules for eliciting a desired therapeutic effect and may include, for example, organic and inorganic small molecules, peptides and polypeptides, polymers, fusion proteins, polynucleotides, oligonucleotides, antibodies or antibody fragments, macromolecules, encapsulated molecules, among others.
- therapeutic agents for treating or preventing a muscle condition or disease characterized by impaired insulin-dependent signaling are described.
- the therapeutic agent is an "activator of the insulin signaling pathway” that preferably exerts its effects, at least in part, downstream of IRS-1.
- activation may occur directly (e.g. via activation, stimulation or up-regulation of an activating component of a signaling pathway) or may occur indirectly (e.g. via inhibition or down-regulation of an inhibitory component of the pathway). The converse is also true where “inhibition” may occur directly or indirectly.
- Activators of the insulin signaling pathway may act at a genetic level, for example, to upregulate or downregulate the expression of a gene of interest, or they may act at the protein level, for example, to increase or decrease the activity of a polypeptide of interest.
- exemplary activators of the insulin signaling pathway may include activators or inhibitors of one or more downstream effector molecules in the insulin signaling pathway (e.g. IRS-1/AKT/GSK3).
- Activators of the insulin signaling pathway may also target molecules that affect the insulin signaling pathway, such as AMPK and JNK1.
- the therapeutic agent may be an AKT activator, AMPK activator, GSK3 ⁇ inhibitor, or JNK1 inhibitor, among others.
- the activator of the insulin signaling pathway is an
- AMPK activator examples include A-769662 9 (a non-nucleoside compound from the thienopyridone family), GW-501516 (which activates PPAR-gamma and AMPK), and AICAR (aminoimidazole carboxamide ribonucleotide). As a combination therapy, GW-501516 has been shown to act synergistically with AICAR.
- the thiazolidinedione (activators of PPAR-gamma) class of drugs may also be considered AMPK activators.
- the activator of the insulin signaling pathway is a JNK inhibitor.
- Exemplary JNK inhibitors include, for example, SP600125 and BI-78D3.
- the therapeutic agent which activates the insulin signaling pathway is an organic or inorganic small molecule.
- "Small molecule”, as used herein, generally means a low molecular weight (e.g. less than 1000Da, often less than 800Da, often than 500Da) organic compound.
- a subunit of a polymer, or a small peptide can be considered within the definition of a small molecule.
- the therapeutic agent is a biguanide or an analogue or derivative thereof.
- Biguanides include, for example, metformin, phenformin, buformin, and proguanil.
- the biguanide or biguanide derivative selected should be capable of treating impaired insulin-dependent signaling in a muscle condition or disease characterized thereby, for example, by activating the insulin signaling pathway whether directly or indirectly.
- the biguanide is metformin (N, N- dimethylimidodicarbonimidicdiamide) or an analogue or derivative thereof.
- Metformin has the following structural formula (Formula I):
- Metformin has been widely prescribed for over 50 years to treat insulin resistance in diabetic patients.
- the present disclosure provides for the re-purposing of a safe and well-established anti-diabetic drug to provide a new and effective treatment for a muscle disease or condition characterized by impaired insulin- dependent signaling.
- Metformin has a low toxicity profile. The most serious complication associated with metformin is lactic acidosis, which has an incidence of about 0.03 cases per 1000 patients years of treatment and a mortality risk of about 0.015 per 1000 patient- years. Most cases occur in patients with impaired renal function (e.g. serum creatinine level >130 ⁇ mol/L or >1.5 g/L).
- metformin is commercially available from a variety of sources.
- the therapeutic agent is a derivative of a biguanide.
- derivative includes, but is not limited to, prodrug forms, pegylated forms, etc.
- prodrug approach is a chemical approach using reversible derivatives, which can be useful in optimizing the clinical application of a therapeutic agent.
- Prodrugs have been designed and developed, for example, to overcome pharmaceutical and pharmacokinetic barriers in clinical drug application, such as low oral drug absorption, lack of site specificity, chemical instability, toxicity, and poor patient acceptance (Han, 2000).
- prodrug generally refers to a compound that, upon in vivo administration, is metabolized or otherwise converted to the biologically, pharmaceutically or therapeutically active form of the compound.
- the pharmaceutically active compound is modified such that the active compound is regenerated, enzymatically or nonenzymatically, to exert a therapeutic effect.
- the prodrug may be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug.
- the therapeutic agent is a prodrug of a biguanide.
- the biguanide prodrug is a compound of Formula II:
- R1 and R2 are independently selected from the group consisting of H, alkyl, alkoxy, haloalkyl, hydroxyalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, alkylene- O-alkyl, alkylene-O-cycloalkyl, alkylene-O-heterocycloalkyl, alkylene-O-alkylene- cycloalkyl, alkylene-O-alkylene-heterocycloalkyl, C(O)-alkyl, C(OO)-alkyl, C(0)-cycloalkyl, C(00)-cycloalkyl, C(0)-heterocycloalkyl, S(0) 2 -heterocycloalkyl, alkylene-O-aryl, al
- R3 is selected from the group consisting of Cr to C 8 -lower alkyl, Cr to C 8 -lower alkoxy, C 1 - to C 8 -lower alkyl-ester, cycloalkyl, heterocycloalkyl, bicycloalkyl, heterobicycloalkyl, aryl, heteroaryl, optionally-substituted aryl, optionally-substituted hetero-aryl; hydroxyalkyl, hydroxycycloalkyl, hydroxy-heterocycloalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, alkylaryl, alkylheteroaryl, alkylene-O-alkyl, alkylene-O-cycloalkyl, alkylene-O-heterocycloalkyl, alkylene-O-alkylene- cycloalky
- X is selected from the group consisting of lower-alkyl, O, C(O), C(O) 2 , C(O)N, S, S(O), S(O) 2 and P(O) 3 ;
- the compound of Formula Il comprises a compound of any one of Formula NA, NB, NC, ND or NE:
- R1 and R2 are independently selected from the group consisting of H, alkyl, alkoxy, haloalkyl, hydroxyalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, alkylene- O-alkyl, alkylene-O-cycloalkyl, alkylene-O-heterocycloalkyl, alkylene-O-alkylene- cycloalkyl, alkylene-O-alkylene-heterocycloalkyl, C(O)-alkyl, C(OO)-alkyl, C(0)-cycloalkyl, C(00)-cycloalkyl, C(0)-heterocycloalkyl, S(0) 2 -heterocycloalkyl, alkylene-O-aryl, al
- R4 is selected from the group consisting of H, hydroxy, halogen, cyano, nitro, carboxylic ester, carboxylic acid, carboxylic amide, C 1 - to C 8 -lower alkyl, C 1 - to C 8 -lower alkoxy, C 1 - to C 8 -lower alkyl-ester, cycloalkyl, heterocycloalkyl, bicycloalkyl, heterobicycloalkyl, aryl, heteroaryl, optionally-substituted aryl, optionally-substituted hetero-aryl; hydroxyalkyl, hydroxycycloalkyl, hydroxy-heterocycloalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, alkylaryl, alkylheteroaryl, alkylene-O- alkyl, alkylene
- R5 to R8 are independently selected from the group consisting of C 1 - to C 8 -lower alkyl, C 1 - to C 8 -lower alkoxy, C 1 - to C 8 -lower alkyl-ester, halo-alkyl-ester cycloalkyl, heterocycloalkyl, bicycloalkyl, heterobicycloalkyl, aryl, heteroaryl, optionally-substituted aryl, optionally-substituted hetero-aryl; hydroxyalkyl, hydroxycycloalkyl, hydroxy- heterocycloalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, alkylaryl, alkylheteroaryl, alkylene-O-alkyl, alkylene-O-cycloalkyl, alkylene-O-heterocycloal
- n is selected from 1 to 4 and m from 0 to 2;
- R1 and R2 are independently selected from the group consisting of alkyl, cycloalkyl and heterocycloalkyl;
- R8 are independently selected from the group consisting of C 1 - to C 8 -lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; and/or a pharmaceutically-acceptable salt, hydrate, solvate, isoform, tautomer, optical isomer, or combination thereof;
- Some exemplary prodrugs include the following compounds, their pharmaceutically acceptable salts, hydrates, solvates, optical isomers, and combinations thereof:
- Acid addition salts of the compounds of Formula Il are most suitably formed from pharmaceutically acceptable acids, and include for example those formed with inorganic acids e.g. hydrochloric, sulphuric or phosphoric acids and organic acids e.g. succinic, maleic, acetic or fumaric acid.
- Other non-pharmaceutically acceptable salts e.g. oxalates may be used for example in the isolation of compounds of Formula Il for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
- base addition salts such as sodium, potassium and ammonium salts
- solvates and hydrates of compounds disclosed herein are also included within the scope.
- prodrug compounds of Formula NA wherein R1 and R2 are independently selected from alkyl group, and X-R3 is either substituted protected p-amino or p-hydroxybenzylic groups, can be prepared in accordance with Scheme 1.
- a method of preparing a compound of Formula NB wherein R1 and R2 are independently selected from alkyl group, and X-R3 is a carbamic ester group, can be generally prepared in accordance with Scheme 2.
- N, N-dialkyl-metformin derivative A with an appropriate chloroformate (e.g. Benzyl chloroformate and 2,2,2-Trichloroethyl chloroformate) in a polar solvent, such as MeCN at 0 0 C under argon led, after purification by flash chromatography to the targeted prodrug compounds D.
- chloroformate e.g. Benzyl chloroformate and 2,2,2-Trichloroethyl chloroformate
- the biguanide prodrug compounds described by Formula NC, wherein R1 and R2 are independently selected from alkyl group, and X-R3 is an alkyl-ester, can be generally prepared in accordance with Scheme 3.
- ND wherein R1 and R2 are independently selected from alkyl group, and X-R3 is a substituted cyclic phosphate, can be prepared in accordance with Scheme 4.
- N, N-dialkyl-metformin derivative A Condensation of N, N-dialkyl-metformin derivative A with an appropriate substituted cyclic phosphoryl chloride (e.g. 2-Chloro-4-phenyl-[1 ,3,2]dioxa-phosphinane 2-oxide) and 1-methylimidazole in MeCN at 0 0 C under argon to provide, after stirring overnight at room temperature and purification by flash chromatography, biguanide prodrug cyclic phosphates F.
- an appropriate substituted cyclic phosphoryl chloride e.g. 2-Chloro-4-phenyl-[1 ,3,2]dioxa-phosphinane 2-oxide
- 1-methylimidazole in MeCN at 0 0 C under argon
- biguanide prodrug compounds of Formula IE wherein R1 and R2 are independently selected from alkyl group, X is Sulfur and -R3 is alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, can generally be prepared in accordance with Scheme 5.
- the compound of Formula Il is pharmaceutically- acceptable salt, optical isomer, or combination thereof.
- the pharmaceutically-acceptable salt comprises an acid addition salt or a basic addition salt.
- the prodrug compounds may have one or more asymmetric centres and it is intended that any optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof are included within the scope of the present application.
- some of the compounds disclosed herein may exist in different tautomeric forms and it is intended that any tautomeric forms which the compounds are able to form are included within the scope of the present application.
- the acid addition salt is formed from hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acid metal salt, monocarboxylic acids, dicarboxylic acids, or tricarboxylic acids.
- the compounds disclosed herein may have asymmetric centers, chiral axes, and chiral planes (e.g., as described in: E. L. Eliel and S. H. Wilen, Stereochemistry of Carbon Compounds, John Wiley & Sons, New York, 1994, pages 1 1 19- 1 190), and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers and mixtures thereof, including optical isomers, being included in the present disclosure.
- alkyl as used herein means a straight- or branched-chain hydrocarbon radical; in one aspect, having from one to eight carbon atoms, and includes, for example, and without being limited thereto, methyl, ethyl, propyl, isopropyl, t-butyl and the like.
- alkyl encompasses substituted alkyl.
- Substituted alkyl includes, for example, and without being limited thereto, haloalkyl, hydroxyalkyl, cyanoalkyl, and the like. This is applied to any of the groups mentioned herein. Groups such as “alkenyl”, “alkynyl", “aryl”, etc. encompass substituted “alkenyl", “alkynyl", “aryl”, etc.
- alkenyl as used herein means a straight- or branched-chain alkenyl radical; in one aspect, having from two to eight carbon atoms, and includes, for example, and without being limited thereto, ethenyl, 1-propenyl, 1-butenyl and the like.
- alkenyl encompass radicals having "cis” and “trans” orientations, or alternatively, "E” and "Z” orientations.
- alkynyl as used herein means a straight- or branched-chain alkynyl radical; in one aspect, having from two to eight carbon atoms, and includes, for example, and without being limited thereto, 1-propynyl (propargyl), 1-butynyl and the like.
- cycloalkyl as used herein means a carbocyclic system (which may be unsaturated) containing one or more rings wherein such rings may be attached together in a pendent manner or may be fused. In one aspect, the ring(s) may have from three to seven carbon atoms, and includes, for example, and without being limited thereto, cyclopropyl, cyclohexyl, cyclohexenyl and the like.
- heterocycloalkyl as used herein means a heterocyclic system
- the ring(s) may have a three- to seven- membered cyclic group and includes, for example, and without being limited thereto, piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuranyl and the like.
- alkoxy as used herein means a straight- or branched-chain alkoxy radical; in one aspect, having from one to eight carbon atoms and includes, for example, and without being limited thereto, methoxy, ethoxy, propyloxy, isopropyloxy, t- butoxy and the like.
- halo means halogen and includes, for example, and without being limited thereto, fluoro, chloro, bromo, iodo and the like, in both radioactive and non-radioactive forms.
- alkylene as used herein means a difunctional branched or unbranched saturated hydrocarbon radical; in one aspect, having one to eight carbon atoms, and includes, for example, and without being limited thereto, methylene, ethylene, n-propylene, n-butylene and the like.
- alkenylene as used herein means a difunctional branched or unbranched hydrocarbon radical; in one aspect, having two to eight carbon atoms, and having at least one double bond, and includes, for example, and without being limited thereto, ethenylene, n-propenylene, n-butenylene and the like.
- alkynylene as used herein means a difunctional branched or unbranched hydrocarbon radical; in one aspect, having two to eight carbon atoms, and having at least one triple bond, and includes, for example, and without being limited thereto, ethynylene, n-propynylene, n-butynylene and the like.
- aryl alone or in combination, as used herein means a carbocyclic aromatic system containing one or more rings wherein such rings may be attached together in a pendent manner or may be fused.
- aryl is one, two or three rings.
- the aryl has five to twelve ring atoms.
- aryl encompasses aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl.
- the "aryl” group may have 1 to 4 substituents such as lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy, lower alkylamino and the like.
- heteroaryl alone or in combination, as used herein means an aromatic system having at least one heteroatom selected from N, S and/or O and containing one or more rings wherein such rings may be attached together in a pendent manner or may be fused.
- heteroaryl is one, two or three rings.
- the heteroaryl has five to twelve ring atoms.
- heteroaryl encompasses heteroaromatic radicals such as pyridyl, indolyl, furyl, benzofuryl, thienyl, benzothienyl, quinolyl, oxazolyl and the like.
- the "heteroaryl” group may have 1 to 4 substituents such as lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy, lower alkylamino and the like.
- substituents and substitution patterns on the compounds disclosed herein may be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, as long as a stable structure results.
- pharmaceutically acceptable salt means either an acid addition salt or a basic addition salt which is compatible with the treatment of patients.
- a “pharmaceutically acceptable acid addition salt” is any non-toxic organic or inorganic acid addition salt of the base compounds represented by Formula Il or any of its intermediates.
- Illustrative inorganic acids which form suitable salts include, but are not limited thereto, hydrochloric, hydrobromic, sulfuric and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
- Illustrative organic acids which form suitable salts include the mono-, di- and tricarboxylic acids.
- Illustrative of such acids are, for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic, p-toluenesulfonic acid and other sulfonic acids such as methanesulfonic acid and 2-hydroxyethanesulfonic acid.
- Either the mono- or di-acid salts can be formed, and such salts can exist in either a hydrated, solvated or substantially anhydrous form.
- the acid addition salts of these compounds are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms.
- the selection criteria for the appropriate salt will be known to one skilled in the art.
- Other non- pharmaceutically acceptable salts e.g. oxalates may be used for example in the isolation of compounds of Formula Il for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
- a "pharmaceutically acceptable basic addition salt” is any non-toxic organic or inorganic base addition salt of the acid compounds represented by Formula Il or any of its intermediates.
- Illustrative inorganic bases which form suitable salts include, but are not limited thereto, lithium, sodium, potassium, calcium, magnesium or barium hydroxides.
- Illustrative organic bases which form suitable salts include aliphatic, alicyclic or aromatic organic amines such as methylamine, trimethyl amine and picoline or ammonia. The selection of the appropriate salt may be important so that an ester functionality, if any, elsewhere in the molecule is not hydrolyzed. The selection criteria for the appropriate salt will be known to one skilled in the art.
- Solvate generally means a compound of Formula Il or the pharmaceutically acceptable salt of a compound of Formula Il wherein molecules of a suitable solvent are incorporated in a crystal lattice.
- a suitable solvent is physiologically tolerable at the dosage administered as the solvate. Examples of suitable solvents, but are not limited thereto, are ethanol, water and the like. When water is the solvent, the molecule is referred to as a hydrate.
- stereoisomers is a general term for all isomers of the individual molecules that differ only in the orientation of their atoms in space. It includes mirror image isomers (enantiomers), geometric (cis/trans) isomers and isomers of compounds with more than one chiral centre that are not mirror images of one another (diastereomers).
- the therapeutic agent may be a peptide or polypeptide (or an active derivative, fragment or variant thereof) that activates the insulin signaling pathway in muscle tissue characterized by defective insulin signaling.
- the peptide or polypeptide may activate or upregulate AMPK or AKT, or may inhibit JNK.
- polypeptide and peptide, as used herein, refer to a sequence of amino acid residues linked together by peptide bonds or modified peptide bonds. Typically, a polypeptide is at least six amino acids long and a peptide is at least 3 amino acids long.
- the polypeptide or peptide can be naturally occurring, recombinant, synthetic, or a combination of these.
- the polypeptide or peptide can be a fragment of a naturally occurring protein or polypeptide.
- polypeptide and peptide also encompass peptide derivatives, peptide analogues, and peptidomimetic compounds. Such compounds are well known in the art.
- a "peptide derivative” is a peptide containing additional chemical or biochemical moieties not normally a part of a naturally occurring peptide.
- Peptide derivatives include peptides in which one or more amino acid side chain and/or the amino-terminus and/or the carboxy-terminus has been derivatized with a suitable chemical substituent group, as well as cyclic peptides, dual peptides, multimers of the peptides, peptides fused to other proteins or carriers glycosylated peptides, phosphorylated peptides, peptides conjugated to lipophilic moieties and peptides conjugated to an antibody or other biological ligand.
- a "peptide analogue” is a peptide comprising one or more non-naturally occurring amino acids.
- Peptidomimetics are compounds that are structurally similar to peptides and contain chemical moieties that mimic the function of the polypeptide or peptide of the present disclosure.
- Polypeptide/peptide derivatives, analogues and peptidomimetics of the present disclosure thus include chimeric molecules that contain two or more chemically distinct regions, each region comprising at least one amino acid or modified version thereof.
- a variant polypeptide or peptide is one in which one or more amino acid residues have been deleted, added or substituted for those that appear in the amino acid sequence of the naturally occurring protein.
- a variant also retains substantially the same activity as the naturally occurring protein.
- they are "conservative" substitutions.
- a conservative substitution involves the replacement of one amino acid residue by another residue having similar side chain properties.
- a polypeptide or peptide analogue, derivative, variant or active fragment has substantially the same or increased activity as compared to a naturally occurring target protein.
- substantially identical activity indicates an activity that is at least about 50%, more typically at least about 60%, 75%, 80%, 90% or 99% of the activity of a naturally occurring protein.
- the analogue, derivative, variant or active fragment exhibits enhanced (increased) activity compared to a naturally occurring protein, preferably a human protein.
- the term “about” refers to a +/-5% variation from the nominal value.
- polypeptides can be prepared by methods known in the art, such as purification from cell extracts or the use of recombinant techniques.
- Shorter sequences can also be chemically synthesized by methods known in the art including, but not limited to, exclusive solid phase synthesis, partial solid phase synthesis, fragment condensation or classical solution synthesis (Merrifeld (1963) Am. Chem. Soc. 85:2149; Merrifeld (1986) Science 232:341).
- the polypeptides for use in accordance with the present disclosure can be purified using standard techniques such as chromatography (e.g. ion exchange, affinity, and sizing column chromatography or high performance liquid chromatography), centrifugation, differential solubility, or by other techniques familiar to a worker skilled in the art.
- polypeptides can also be produced by recombinant techniques.
- this involves transformation (including transfection, transduction, or infection) of a suitable host cell with an expression vector comprising a polynucleotide encoding the protein or polypeptide of interest.
- a suitable host cell with an expression vector comprising a polynucleotide encoding the protein or polypeptide of interest.
- an expression vector comprising a polynucleotide encoding the protein or polypeptide of interest.
- the nucleic acid sequences for human JNK1 and AMPK genes and various other components involved in the insulin signaling pathway are known in the art. These may be used as a basis for making the polynucleotides.
- the polynucleotides can be derived or purified from a suitable source by standard techniques.
- the polynucleotides can be genomic DNA or RNA or they can be cDNA prepared from isolated mRNA. Alternatively, the known sequences may be used to prepare probes to obtain other nucleic acid sequences encoding the polypeptide from various sources using standard techniques.
- Polynucleotides encoding fragments or variants of the naturally occurring proteins of interest can be constructed by deletion, addition, and/or substitution of one or more nucleotides within the coding sequence using standard techniques, such as site- directed mutagenesis techniques.
- polypeptides and peptides can also be produced as fusion proteins.
- initiation signals may be required for efficient translation of cloned polynucleotide. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire wild-type gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, additional translational control signals may not be needed. In other cases, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. [00147] Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert.
- exogenous translational control signals and initiation codons can be natural or synthetic.
- the efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements and/or transcription terminators (Bittner et al. (1987) Methods in Enzymol. 153, 516).
- Suitable expression vectors for use with the nucleic acid sequences include, but are not limited to, plasmids, phagemids, viral particles and vectors, phage and the like.
- baculovirus expression vectors are suitable.
- viral expression vectors such as cauliflower mosaic virus and tobacco mosaic virus
- plasmid expression vectors such as the Ti plasmid
- the entire expression vector, or a part thereof, can be integrated into the host cell genome. In some circumstances, it is desirable to employ an inducible expression vector as known in the art.
- an inducible expression vector e.g. the LACSWITCH Inducible Expression System (Stratagene, LaJoIIa, CA).
- LACSWITCH Inducible Expression System (Stratagene, LaJoIIa, CA).
- the precise host cell used is not critical.
- the polypeptide or peptide can be produced in a prokaryotic host (e.g., E. cold or B.
- subtilis or in a eukaryotic host (e.g., Saccharomyces or Pichia; mammalian cells, such as COS, NIH 3T3, CHO, BHK, 293, or HeLa cells, insect cells, or plant cells).
- Saccharomyces or Pichia mammalian cells, such as COS, NIH 3T3, CHO, BHK, 293, or HeLa cells, insect cells, or plant cells.
- transformation or transfection and the choice of expression vector will depend on the host system selected and can be readily determined by one skilled in the art. Transformation and transfection methods are described, for example, in Ausubel et al. (1994) CurrentProtocols in Molecular Biology, John Wiley & Sons, New York; and various expression vectors may be chosen from those provided, e.g. in Cloning Vectors: A Laboratory Manual (Ponwels et al., 1985, Supp.
- a host cell may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in a specific, desired fashion. Such modifications (e.g. glycosylation) and processing (e.g. cleavage) of protein products may be important for the activity of the protein.
- Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen by one skilled in the art to ensure the correct modification and processing of the expressed heterologous protein.
- the host cells harboring the expression vehicle can be cultured in conventional nutrient media adapted as needed for activation of a chosen gene, repression of a chosen gene, selection of transformants, or amplification of a chosen gene according to known procedures.
- the present disclosure also contemplates antisense oligonucleotides to various genes of interest, for example, JNK1.
- the therapeutic agent is a JNK1 antisense oligonucleotide Inhibition of JNK, which inhibits the insulin-signaling pathway, would indirectly activate the pathway by restoring the response to insulin.
- siRNAs short interfering double-stranded RNA molecules
- siRNA interference mediated by siRNAs is known in the art to play an important role in post-transcriptional gene silencing [Zamore, Nature Struc. Biol., 8:746-750 (2001)]
- siRNA molecules are typically 21-22 base pairs in length and are generated when long double- stranded RNA molecules are cleaved by the action of an endogenous ribonuclease.
- the oligonucleotide modulators can be prepared by conventional techniques well-known to those skilled in the art.
- the oligonucleotides can be prepared using solid-phase synthesis using commercially available equipment, such as the equipment available from Applied Biosystems Canada Inc. (Mississauga, Canada).
- the oligonucleotide modulators can be prepared by enzymatic digestion and/or amplification of the naturally occurring target gene or mRNA, or of cDNA synthesized from the mRNA, using standard techniques known in the art.
- the oligonucleotide inhibitors comprise RNA
- they can be prepared by in vitro transcription methods also known in the art.
- siRNA molecules can also be conveniently prepared using commercially available in vitro transcription kits.
- Oligonucleotides can also be prepared using recombinant DNA techniques.
- the therapeutic agent is an anti-diabetic agent selected from the group consisting of insulin, insulin mimetics, and insulin secretagogues.
- antidiabetic agents include insulin, insulin mimetics, insulin analogues, biguanides (e.g. metformin, phenformin), meglitinides (e.g.
- repaglinide nateglinide
- biguanide/glyburide combinations e.g., Glucovance®
- insulin secretagogues incretins
- insulin sensitizers e.g., metformin, glitazones, and thiazolidinediones
- sulfonylureas e.g., glimepiride, glyburide, gliclazide, chlorpropamide, glipizide, gliamilide, acetohexamide, glibenclamide, tolazamide, and tolbutamide
- thiazolidinediones e.g., troglitazone, rosiglitazone and pioglitazone.
- the insulin secretagogue is a sulfonylurea or a meglitinide.
- the anti-diabetic agent is selected from insulin, an insulin analogue, a co-secreted agent, pramlinitide, and a DPP4 antagonist.
- the anti-diabetic drug may be a PPAR-a agonist,
- the therapeutic agent is a an insulin sensitizers
- the therapeutic agent is a modulator of insulin signaling.
- modulator refers to both activators and inhibitors of a signaling event.
- the modulator may include, for example, any drug that improves insulin resistance and/or enhances muscle metabolism.
- Modulators may, for example, include activators of insulin signaling.
- the therapeutic agents disclosed herein may be administered alone but, more typically, will be incorporated into a composition for the treatment and/or prevention of a muscle condition or disease characterized by impaired insulin-dependent signaling.
- compositions and methods of preparing them are known in the art and are described, for example, in “Remington: The Science and Practice of Pharmacy” (formerly “Remingtons Pharmaceutical Sciences”); Gennaro, A., Lippincott, Williams & Wilkins, Philadelphia, PA (2000).
- compositions for the treatment and/or prevention of a muscle condition or disease characterized by impaired insulin-dependent signaling comprise one or more therapeutic agents that act, at least in part, by activating the insulin signaling pathway, which is now known to be impaired in certain muscle diseases and conditions.
- the therapeutic agent may be any one or more of the therapeutic agents described herein.
- the pharmaceutical composition may comprise one or more therapeutic agents, or active ingredients, together with one or more pharmaceutically acceptable diluents, carriers or excipients.
- a "pharmaceutically acceptable" diluent, carrier or excipient is a material that is mixed with the therapeutic agent in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to a patient, the material being generally non-toxic when administered to a patient.
- Pharmaceutically acceptable diluents, carriers, and excipients are well known to those of skill in the art.
- the composition may comprise one or more additional therapeutic agents.
- the additional therapeutic agent comprises an agent for promoting muscle regeneration or repair.
- the composition may comprise one or more stem cell modulators, one or more muscle stem cells, or a combination thereof.
- the additional therapeutic agent is a corticosteroid
- Corticosteroids are currently the first-line therapy for certain muscle diseases, e.g. muscular dystrophies, and it is expected that the combination of a corticosteroid with a therapeutic agent that activates the insulin signaling pathway would provide significant benefit to patients.
- Corticosteroids include natural and synthetic compounds having glucocorticoid and/or mineralocorticoid activity. Natural corticosteroids are synthesized from cholesterol within the adrenal cortex. Synthetic drugs with corticosteroid-like effect are used to treat a variety of conditions and diseases.
- Dexamethasone and its derivatives are almost pure glucocorticoids, while prednisone and its derivatives have some mineralocorticoid action in addition to the glucocorticoid effect.
- Deflazacort a prodrug with glucocorticoid properties, has approximately 70-90% potency compared to prednisone.
- the corticosteroid is prednisone. In some embodiments, the corticosteroid is prednisolone. In some embodiments, the corticosteroid is deflazacort. In some embodiments, the corticosteroid is dexamethasone. [00170] The optimal dosage of corticosteroid, when used in combination with a therapeutic agent that activated the insulin signaling pathway, can be determined by a person of skill in the art, for example, by titration.
- a single composition comprises two or more therapeutic agents.
- a single composition comprises metformin and a corticosteroid (e.g. one or more of prednisone, prednisolone, deflazacort, or dexamethasone).
- metformin and a corticosteroid are comprised in two separate compositions. The metformin may be administered prior to, concurrently with, or subsequent to the corticosteroid in a combination therapy.
- Administration of the pharmaceutical compositions disclosed herein may be by any of a number of routes depending upon whether local or systemic treatment is desired, and upon the area to be treated.
- the compositions are administered locally.
- the compositions are administered systemically.
- compositions may be formulated, for example, for enteral administration, topical administration, parenteral administration, or pulmonary administration.
- Enteral administration may comprise, for example, oral, sublingual, rectal or vaginal administration.
- the composition is for oral administration.
- the compositions may be formulated in the form of tablets, capsules, lozenges, chewing gum, troches, powders, syrups, elixirs, aqueous solutions and suspensions, and the like.
- carriers may be used, including, for example, lactose, sodium citrate and salts of phosphoric acid.
- disintegrants such as starch, and lubricating agents such as magnesium stearate and talc, are also commonly used in tablets.
- useful diluents include, for example, lactose and high molecular weight polyethylene glycols. If desired, certain sweetening and/or flavoring agents can be added.
- Parenteral administration may comprise, for example, intramuscular, subcutaneous, intravenous, intrarterial, intracerebral, intraperitoneal, intracardiac, intrathecal or intraosseous administration.
- the parenteral administration is intramuscular administration.
- the parenteral administration is subcutaneous administration.
- the parenteral administration is intravenous administration.
- compositions are administered by injection or infusion.
- sterile solutions are usually prepared, and the pHs of the solutions are suitably adjusted and buffered.
- the total concentration of solutes should be controlled to render the preparation isotonic.
- compositions for parenteral administration can be administered, for example, by injection as a solution or suspension in a pharmaceutically acceptable liquid medium, e.g. oil or aqueous medium or emulsion.
- a pharmaceutically acceptable liquid medium e.g. oil or aqueous medium or emulsion.
- the composition can be administered in a biocompatible medium which is, or becomes in site, a semi-solid or solid matrix.
- the matrix maybe an injectable liquid which forms a semi-solid gel at the site of tissue damage or degeneration, such as matrices comprising collagen and/or its derivatives, polylactic acid or polyglycolic acid, or it may comprise one or more layers of a flexible, solid matrix that is implanted, such as impregnated fibrous matrices.
- parenteral administration may include the use of a pump for periodic or continuous delivery.
- the composition is formulated for topical administration.
- Topical administration may include, for example, delivery via the skin or the mucous membranes of, for example, the eyes, nose, urethra, rectum or vagina.
- the topical composition may be in the form of, for example, a cream, lotion, gel, paste or ointment.
- topical administration may include, for example, the use of a patch or other transdermal delivery device.
- ointments or droppable liquids may be delivered by ocular delivery systems known to the art such as applicators or eye droppers.
- Suppository dosage forms are useful for vaginal, urethral and rectal administration.
- Such suppositories will generally be constructed of a mixture of substances that is solid at room temperature but melts at body temperature.
- the substances commonly used to create such vehicles include the obroma oil, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weight and fatty acid esters of polyethylene glycol.
- Analogous gels or creams can be used for vaginal, urethral and rectal administrations.
- the composition is for administration by pulmonary route, for example, by inhalation or insufflation of powders or aerosols, for example, using a nebulizer.
- pulmonary route for example, by inhalation or insufflation of powders or aerosols, for example, using a nebulizer.
- aerosol administration diluents and/or carriers selected will be appropriate to allow the formation of an aerosol.
- the composition is for intranasal administration.
- compositions described herein may be delivered in combination with a pharmaceutically acceptable vehicle.
- a pharmaceutically acceptable vehicle Preferably, such a vehicle would enhance the stability and/or delivery properties.
- Numerous administration vehicles will be apparent to those of ordinary skill in the art, including without limitation, slow release formulations, liposomal formulations, microparticles, microcapsules and polymeric matrices.
- the composition comprises a pharmaceutically acceptable acid addition salt or a pharmaceutically acceptable base addition salt.
- Examples of pharmaceutically acceptable acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, p-toluenesulphonic and arylsulphonic acids, for example.
- Examples of pharmaceutically acceptable base addition salts include those derived from non-toxic metals such as sodium or potassium, ammonium salts and organo-amino salts such as triethylamine salts. Numerous appropriate such salts will be known to those of ordinary skill.
- the dosage regimen for a composition as disclosed herein may be selected or optimized n accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular therapeutic agent(s) being administered.
- a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the therapeutic agent or composition required to treat and/or prevent the disease or condition characterized by impaired insulin dependent signaling.
- treatment will generally be initiated with small dosages less than the optimum dose of each therapeutic agent. Thereafter, the dosage is increased until the optimum effect under the circumstances is reached.
- the pharmaceutical compositions are administered at a concentration that will generally afford effective results without causing harmful or deleterious side effects.
- Administration can be either as a single unit dose or, if desired, the dosage can be divided into convenient subunits that are administered at suitable times throughout the day.
- dosages are often selected to maintain a serum level of the therapeutic agent between about 0.01 ⁇ g/cc and about 1000 ⁇ g/cc, or between about 0.1 ⁇ g/cc and about 100 ⁇ g/cc.
- an alternative measure of administration amount is from about 0.001 mg/kg to about 10 mg/kg (e.g. from about 0.01 mg/kg to about 10 mg/kg), or from about 0.01 mg/kg to about 1 mg/kg (e.g. from about 0.1 mg/kg to about 1 mg/kg), will be administered.
- an alternative measure of administration amount is from about 0.001 mg/kg to about 10 mg/kg (e.g.
- the present disclosure contemplates methods for the prevention and/or treatment of a muscle condition or disease characterized by impaired insulin-dependent signaling.
- the treatment methods may be applied to any muscle disease or condition that is characterized by the signaling defect.
- the method comprises administering to a subject in need thereof a therapeutic agent as described herein.
- a subject in need thereof may be a subject that has, is suspected of having, or is at risk of developing a muscle disease or condition characterized by impaired insulin-dependent signaling.
- the therapeutic agent preferably activates the insulin signaling pathway downstream of IRS-1 , either directly or indirectly, thereby targeting the underlying signaling defect in the muscle tissue.
- treat or “treating” generally means to alleviate symptoms or pathology of a muscle disease or condition characterized by impaired insulin-dependent signaling, eliminate the causation of the symptoms or pathology, either on a temporary or permanent basis, or to inhibit or delay the onset of symptoms or pathology of the named disease or condition.
- the term “prevent” generally means to inhibit or delay the onset of symptoms or pathology of a muscle disease or condition characterized by impaired insulin-dependent signaling.
- the term “therapeutically effective amount” means an amount of the therapeutic agent which is effective in treating or preventing the named disorder or condition without eliciting significant adverse effects.
- Tests can be performed by those of skill in the art, including those tests described in the Examples section, to determine whether a given muscle disease or condition is characterized by defective insulin signaling in muscle tissue, and also to determine whether a particular patient would benefit from a treatment method disclosed herein.
- correction of the underlying signaling defect may result in one or more of the following: reduced clinical pathology, reduced symptoms, delayed onset or progression of disease, enhanced mobility, increased muscle mass, increased muscle strength, improved contractile properties, increased muscle regeneration, increased repair of damaged or defective tissue, and/or prevention of muscle atrophy.
- the selected therapeutic agent or composition may be administered as a monotherapy or as part of a combination therapy.
- the therapeutic agent is administered in a monotherapy.
- the therapeutic agent for activating the insulin signaling pathway is administered as part of a combination therapy with another therapeutic agent, in particular, a therapeutic agent that targets other pathways. Some overlap in the pathways targeted is, of course, permitted.
- method comprises administration of metformin or an analogue or derivative thereof, in a combination therapy.
- metformin may be co-administered with a corticosteroid, such as prednisone, prednisolone, deflazacort, or dexamethasone, among others.
- the corticosteroid may be administered to the subject prior to, concurrently with, or subsequent to the therapeutic agent.
- the combination therapy with metformin is expected to provide a significant advantage in that standard therapeutic doses of corticosteroids may be reduced, thereby reducing the side effects associated with these drugs.
- evaluation of the therapeutic agents described herein may be accomplished through in vitro, ex vivo and/or in vivo assays that are well known in the art, including the assays described below. Additionally, various screening methods known in the art can be employed to identify candidate activators of the insulin signaling pathway. For example, activators that up- or down-regulate a target gene can be identified by monitoring cells treated with the candidate activator for an increase or decrease in the expression of the target gene. Methods such as Northern blot analysis, quantitative RT- PCR or microarray analysis can be used for this purpose.
- an increase or decrease in the corresponding protein level can be monitored, for example, by Western blot analysis.
- Activators or inhibitors that modulate the activation state of a signaling molecule e.g. phosphorylation state
- the binding ability can be determined using one of a variety of binding assays known in the art (see, for example, Coligan et al., (eds.) Current Protocols in Protein Science, J. Wiley & Sons, New York, NY).
- various immunoassays can be used.
- the ability of potential therapeutic agents to rescue tissue from impaired insulin dependent signaling, or to improve behavioral outcomes, can be tested in a suitable animal model.
- One well-established animal model of muscular dystrophy is the mdx mouse model.
- Mouse models for congenital MD include the dy/dy (dystrophia-muscularis) mouse and the allelic mutant dy(2J)/dy(2J) mouse, both presenting significant reduction of alpha2-laminin in the muscle and a severe phenotype.
- the myodystrophy mouse (Large(myd)) harbors a mutation in the glycosyltransferase Large, which leads to altered glycosylation of alpha-DG, and also a severe phenotype. More recently, using the homologous recombination technique in embryonic stem cell, several mouse models have been developed with null mutations in each one of the four SG genes. All sarcoglycan-null animals display a progressive muscular dystrophy of variable severity and share the property of a significant secondary reduction in the expression of the other members of the sarcoglycan subcomplex and other components of the Dystrophin-glycoprotein complex.
- muscle proteins include the knockout mouse for myostatin, which demonstrated that this protein is a negative regulator of muscle growth. Additionally, the stress syndrome in pigs, caused by mutations in the porcine RYR1 gene, helped to localize the gene causing malignant hypertermia and Central Core myopathy in humans.
- the canine golden retriever MD model (the best characterized dog model), the disease results from a single base pair change in the 30 consensus splice site of intron 6, leading to skipping of exon 7 and alteration of the reading frame in exon 8, which creates a premature stop (Sharp NJ, et al. Genomics 1992 13(1): 1 15—121).
- This model represents a clinically similar model of DMD due to the large size of the animal and significant muscle weakness.
- Autosomal recessive limb-girdle MD forms models include the SJL/J mice, which develop a spontaneous myopathy resulting from a mutation in the Dysferlin gene, being a model for LGMD2B.
- the BIO14.6 hamster is the spontaneous animal model for delta-SG deficiency, whereas some canine models with deficiency of SG proteins have also been identified (Willmann R. et al. Neuromuscular Disorders 2009 19 241-249; Vainzof M. et al. J MoI Neurosci. 2008 34(3):241-8).
- Activators of the insulin signaling pathway such as metformin and analogues and derivatives thereof, are expected to provide benefit in forms of disease characterized by impaired insulin-dependent signaling.
- the ability of the compound(s) and treatments to repair damaged muscle tissue can be tested, for example, by administering the compound(s) or treatments to mice exposed to freeze-induced or cardiotoxin-induced muscle damage, and monitoring repair of the damaged muscle (see Megeney et al., (1996) Genes Dev., 10:1 173-1 183; Asakura et al., (2000) J: Cell Biol., 159:123- 134).
- a method of determining whether a subject suffering from a muscle disease or condition would benefit from treatment with an activator of the insulin signaling pathway.
- the method comprises obtaining a biological sample from the subject; and testing the sample for impaired insulin dependent signaling, wherein the identification of impaired insulin dependent signaling is indicative that the patient would benefit from treatment with an activator of the insulin signaling pathway.
- the sample may be, for example, a cell or tissue sample.
- the cell or tissue may be blood-derived or muscle-derived.
- the sample is a muscle cell or muscle tissue.
- kits comprising the therapeutic agents and/or compositions disclosed herein.
- the commercial packages or kits may comprise one or more therapeutic agents together with instructions for use in the prevention and/or treatment of a muscle disease or condition characterized by impaired insulin dependent signaling.
- therapeutic kits are provided comprising one or more therapeutic agents in pharmaceutical compositions.
- the kit is a diagnostic kit, for example, to identify a patient that may benefit from treatment with a particular therapeutic agent or composition.
- kits Individual components of the kit could be packaged in separate containers and, associated with such containers, can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human or animal administration.
- the liquid solution can be an aqueous solution, for example, a sterile aqueous solution.
- the container means may be a sealed pouch or vial, an inhalant, syringe, pipette, eye dropper, or other such like apparatus, from which the composition may be administered to a patient.
- kits may also be provided in dried or lyophilized form and the kit can additionally contain a suitable solvent for dissolution or reconstitution of the components. Irrespective of the number or type of containers, the kits also may comprise an instrument for assisting with the administration of the composition to a patient.
- FIG. 1 A schematic representation of insulin-dependent signaling pathways is shown in Figure 1. Following the binding of insulin to its cognate receptor, the receptor is subject to tyrosine autophosphorylation, which recruits and activates adapter/signaling proteins such as IRS-1. IRS-1 serves as a focal point for the activation of multiple insulin- dependent signaling cascades, i.e. as a major docking site for phosphatidylinositol 3- kinase (Pl 3 kinase), which in turn promotes the recruitment of various kinases to membrane locations (AKT) followed by their activation (reviewed in White et al. 2002).
- Pl 3 kinase phosphatidylinositol 3- kinase
- AKT activation is known to act as a prerequisite for insulin-stimulated glucose transport through the recruitment and translocation of the insulin regulated glucose transporter protein, GLUT4, from intracellular storage membranes to the plasma membrane proper, although the precise mechanism remains unknown (Lizcano and Alessi 2002).
- IRS-1/AKT signaling has been established as a crucial pro-survival pathway in skeletal muscle (Sandri et al. 2004; Stitt et al. 2004) and one study has reported that AKT phosphorylation may protect myotube integrity against the loss of dystroglycan function in vitro (Langenbach and Rando et al. 2002).
- JNK1 MAP Kinase
- IRS-1 is subject to inhibitory serine phosphorylation or activating tyrosine phosphorylation (Y941).
- JNK1 can directly phosphorylate the IRS-1 protein at serine 307 leading to inhibition of insulin signaling (Aguirre et al. 2000; Hilder et al. 2004). It is demonstrated herein that JNK1 targets and phosphorylates the insulin receptor substrate IRS-1 at serine 307 in dystrophic muscle with attendant disruptions in insulin mediated signal events and insulin sensitive metabolic responses.
- This serine phosphorylation of IRS-1 is known from the literature to induce insulin resistance and metabolic disturbance in a variety of diabetes-related conditions and obesity. As such, the present inventors postulated that dystrophic skeletal muscle may suffer from similar metabolic limitations.
- dystrophic myofibers are indeed characterized by metabolic perturbations, including loss of glycogen content, altered distribution of the insulin sensitive glucose transporter protein GLUT4 and inhibition in key metabolic regulatory factors such as AKT, AMPK etc., all of which are consistent with an insulin resistant state.
- the inventors postulated that dystrophic muscle pathology may be attenuated by use of compounds or drugs that treat or alleviate insulin resistance.
- the most commonly prescribed drug for treating insulin resistance in Type Il diabetes is metformin.
- metformin The most commonly prescribed drug for treating insulin resistance in Type Il diabetes.
- Metformin was continuously delivered for either a 14-day or 28-day period via the use of implanted osmotic mini-pumps (Alzet minipumps). The animals were closely monitored throughout the study for adverse events and at the end of the indicated time period, animals were euthanized and a variety of skeletal muscles were collected and analyzed for dystrophic muscle characteristics. Metformin-treated animals displayed a significant correction in the dystrophic muscle phenotype.
- metformin treatment led to a reduction in myofiber damage, reduced numbers of centrally located myonuclei (indicative of degenerating and regenerating myofibers), restoration of glycogen concentrations, normal distribution of GLUT4 and upregulation in the metabolic regulatory kinase AKT and down regulation of the catabolic kinase GSK3 ⁇ .
- DMD Duchenne muscular dystrophy
- its related genetic disorders such as Becker's muscular dystrophy, limb girdle muscular dystrophies, among others.
- dystrophic muscle pathology has been understood to arise primarily from mechanical insufficiency, which in turn leads to increased susceptibility of the affected muscle fibers to work related damage.
- the work of the present inventors now indicates that dystrophic muscle also suffers from a general metabolic disturbance which itself may augment or accelerate the evolving pathology.
- therapeutic agents that act to correct the underlying metabolic disturbance such as metformin and its derivatives, can significantly limit the development of dystrophic muscle damage and improve behavioral outcomes, opening an exciting new avenue for therapeutic intervention.
- patients suffering from other muscle diseases and conditions characterized by impaired insulin- dependent signaling may also derive benefit from treatments that target the signaling defect.
- AKT kinase activity was significantly decreased by ⁇ 53% (TA) and -33% (DIA) in dystrophic muscle compared to wild-type muscles (Fig. 3A). Consequently, GSK-3 ⁇ kinase activity was elevated by ⁇ 45% (TA) and -24% (DIA) in mdx animals compared to wild-type control animals (Fig. 3B). These changes in kinase activity are consistent with an inhibition of insulin/IRS-1 signaling (See Fig.1) and suggest that the activity of downstream metabolic regulatory factors is altered in dystrophic skeletal muscle. Taken together, these observations imply that dystrophic skeletal muscle suffers from an inherent metabolic deficiency that may arise from inhibition or reduction in insulin-mediated signaling events.
- Metformin Treatment Improves the Metabolic Profile and limits Pathology in Dystrophic Skeletal Muscle [00222] Based on the results in Examples 1 and 2, studies were conducted to determine whether an insulin mimetic would circumvent the signaling defect and alter the progression of the dystrophic muscle pathogenesis, thereby providing a novel pharmacologic intervention to treat or prevent dystrophic muscle pathology.
- the mimetic selected for testing was metformin.
- Metformin is a standard intervention for type 2 diabetes/insulin resistance and has a post-insulin receptor mode of action (reviewed in Musi and Goodyear 2006). Although metformin and its chemical derivatives have been in clinical use since 1957, the mode of action for this drug has remained unknown until the recent past.
- Metformin is known to stimulate cross-talk between insulin-dependent and insulin-independent signaling pathways, leading to substantial upregulation of AKT and AMPK kinase activities, respectively. Specifically, metformin stimulates the kinase AMPK and, once activated, AMPK activates many insulin-dependent cellular functions, such as enhancing glucose transport, restoring glycogen levels etc., through as yet undefined mechanisms (reviewed in Misra 2008; Zhou et al. 2001 ; Musi et al. 2002 Suwa et al. 2006).
- metformin Since the molecular target of metformin lies downstream of the insulin receptor and IRS-1 , it was predicted that metformin administration would effectively bypass the inherent insulin resistance in dystrophic muscle that may originate from the JNK1 serine phosphorylation of IRS1 , thereby limiting dystrophic muscle pathology. [00223] Studies were conducted in which metformin was administered to 4-week old mdx mice followed by extensive biochemical and morphologic analysis. The 4-week age group coincides with the early muscle degeneration/regeneration cycle and as such tests the ability of metformin to limit the degeneration process that begins at 3-4 weeks of age in this murine model of DMD. Metformin delivery was accomplished with the use of osmotic pump technology (Alzet).
- Alzet osmotic pump technology
- Alzet osmotic pumps are produced in a variety of formats ideal for use in murine models.
- the pumps were preloaded with metformin and then surgically implanted in a subcutaneous position suitable for long-term delivery, i.e. mid-scapular region.
- the Alzet osmotic pump was loaded with a metformin concentration selected to deliver 100mg/kg/bodywt per day, per standard diabetic treatment regimes, at 28 days of continuous infusion (Misra 2008).
- metformin could be given orally or by other routes of administration to humans but the osmotic pump is a convenient way to regulate administration over the 28 days of the murine model.
- Control animals were implanted with osmotic pumps containing saline.
- metformin is an anti-hyperglycemic agent
- blood glucose levels were measured. Animals were closely monitored and no evidence of hypoglycemia or adverse health effects were observed throughout drug treatment.
- AMPK was measured in wild-type and dystrophic muscles (mdx-S, mdx-M). Metformin induced a marked elevation in AMPK kinase activity by 75% (TA) and 55% (DIA) over baseline levels in muscles from mdx-S control (not shown). This confirmed that metformin was active and eliciting a physiological response in dystrophic skeletal muscle.
- TA 75%
- DIA 55%
- Example 4 Metformin Rescues Phosphorylation/Activity of Insulin
- GLUT4 is the AKT-responsive insulin regulated glucose transporter protein. Metformin administration, in addition to AMPK, has been reported to stimulate glucose uptake by promoting translocation of glucose transporters from intracellular pools to the sarcolemma. In normal healthy skeletal muscle, GLUT4 was localized to discrete regions of the plasma membrane/sarcolemma, along with a diffuse cytoplasmic distribution (Fig. 5, WT-S).
- GLUT4 protein to that observed in wild-type skeletal muscle (Fig. 5, MDX-M).
- Fig. 6, WT-S wild-type skeletal muscle
- mdx skeletal muscle displayed abnormal glycogen deposition, with limited or depleted glycogen content in most fibers and excess glycogen content in a small number of fibers (Fig.6, MDX-S).
- Dystrophic muscle pathology in the mdx strain is characterized by variability in myofiber size with extensive myofiber regeneration (as evidenced by myofibers with centrally located nuclei).
- MS dystrophic muscles
- Metformin treatment resulted in a significant reduction in central nuclei with only -38% of mcfx-M dystrophic fibers displaying central nuclei compared to (55%) untreated mcfx-S fibers (Fig. 8C).
- the beneficial effect of metformin in dystrophic muscle was also apparent from analyses of fiber size distribution (based on cross-sectional area).
- Untreated dystrophic muscles exhibited a greater proportion, 22% (TA) and 38% (DIA), of smaller myofibers (CSA ⁇ 1500 ⁇ m 2 ), whereas mdx-M displayed fewer myofibers, 14% (TA) and 23% (DIA), in the same size range (Fig. 8 D and E).
- Myofiber Fragility [00233] Sarcolemma fragility is commonly known to occur subsequent to the loss of dystrophin/DGC in DMD. Since metformin treatment diminished the degeneration of dystrophic muscle, it was investigated whether the improvement in sarcolemmal integrity was associated with restoration of the DGC. It was found that ⁇ -dystroglycan and v- sarcoglycan protein expression were increased compared to the mcfx-Saline (MS) control (Fig. 9A, first and second rows). Similarly, metformin administration increased utrophin protein levels in the gastrocnemius compared to mcfx-Saline control (Fig.
- EBD Evans blue dye
- Example 8 Metformin treated mdx-mice display improved motor performance compared to saline-treated mdx-mice. Mice (mdx) 3-4 weeks of age were treated with metformin or saline for 28 days according to the protocol described above. At the end of the treatment phase, a rotorod test was performed, which was repeated daily for 3 consecutive days. The mice were 7-8 weeks of age when tested, thus young adults. The initial rotorod speed for each trial was 15 rpm with gradual acceleration at a rate of 0.1 rpm per second.
- Mean fall latency time refers to the average amount of time the mice could run on the rotating rod (seconds). As soon as the animals fell from the rod, the time was stopped. The average value shown represents the average of each trial (1-4) performed for 3 consecutive days.
- the rotorod test is a behavioural test of motor coordination or performance and fatigue resistance or exercise tolerance, where the earlier time points are essentially an adaptation to the rotorod. The results indicate that, by the 4 th trial, the metformin-treated mice successfully adapt to the rotorod with a significant improvement in running time. No comparable improvement was seen in the saline-treated mdx mice.
- IRS-1/insulin- dependent signaling is impaired in dystrophic muscle and that circumventing this pathway with insulin mimetics such as metformin, which target JNK1 or effectors of insulin signaling downstream of IRS-1 , may provide a readily accessible therapy to treat and limit dystrophic muscle damage.
- the 3 week age group coincides with the early muscle degeneration/regeneration cycle and used to test the ability of each compound to limit the degeneration process, while 16 weeks of age represents a time of decelerated disease progression, which tested the ability of each compound to reverse or limit the existing pathology.
- prednisolone was administered by intraperitoneal injection every second day at a concentration of 1 uL (approximately 1 mg/kg/day body weight), as in St-Pierre et al. 2004.
- Metformin delivery was accomplished with the use of osmotic pump technology (Alzet) as described above.
- Alzet osmotic pumps are produced in a variety of formats ideal for use in murine models.
- the pumps were preloaded with metformin and then surgically implanted in a subcutaneous position that was suitable for long-term delivery, i.e. mid- scapular region. This enabled delivery of a sustained low dosage over a period of 14 to 28 days at a concentration of 100mg/kg/day.
- Daily doses of about 50 -150 mg/kg/day may also be administered.
- a variety of individual skeletal muscles will be collected, representing the different fiber constituencies (TA, EDL, soleus, gastrocnemius). Muscles will be analyzed and characterized for baseline metabolic status, the phosphorylation and activity status of insulin signaling components and for standard pathologic indices. Baseline metabolic analysis will include a measure of glycogen distribution using periodic acid Schiff staining on muscle sections and glycogen concentrations through standard biochemical analysis (Megeney et al. 1992) and immuno-localization of the insulin-regulated glucose transporter GLUT4.
- Skeletal muscle will also be prepared to measure the phosphorylation status of the insulin receptor substrate (IRS-1), and kinase activity for JNK-1 , AKT, AMPK and GSK3 ⁇ , all of which are altered in the dystrophic muscle milieu. Muscle fiber integrity will also be monitored by counting the number of degenerated/regenerated myofibers (central nucleation), myofiber size and immunoglobin infiltration in each of the conditions outlined above. Appropriate statistical analysis will be conducted (ANOVA, posthoc analysis) to determine significance.
- IRS-1 insulin receptor substrate
- kinase activity for JNK-1 , AKT, AMPK and GSK3 ⁇ all of which are altered in the dystrophic muscle milieu.
- Muscle fiber integrity will also be monitored by counting the number of degenerated/regenerated myofibers (central nucleation), myofiber size and immunoglobin infiltration in each of the conditions outlined above. Appropriate statistical analysis will be conducted (ANOVA, posthoc analysis) to determine significance.
- Example 11 Preparation of prodrug N 1 ,N 1 -Dimethyl-S-cyclohexyl-N 4 Thiohydroxylbiguanidine.
- Example 12 In a similar manner N 1 ,N 1 -Dimethyl-S-phenyl-N 4 thiohydroxylbiguanidine was synthesized.
- Example 19 Preparation of [( ⁇ / 1 , ⁇ / 1 -Dimethylcarbamimidoyl)guanidino]-4- phenyl-1 ,3,2-dioxaphosphoramidate.
- DMD/ mdx were purchased from Jackson Laboratories (Bar Harbour, ME) and housed in the University of Ottawa Animal Care Facility. Mice aged 3-4 weeks (peak necrotic stage) were surgically implanted with an (Alzet) osmotic mini-pump containing metformin or insulin for 14 and 28 days. Animals were randomly assigned to experimental or control treatment groups. Depending on the experiment, Mdx mice either received 100mg/kg/d of metformin (Aldrich) (mcfx-M) or .75 U of insulin (Sigma) (mcfx-l). Drug concentrations were based on the effective dose range used in diabetic mouse models (Bailey and Puah, 1986; Cohen et al., 2004)
- Control groups were surgically implanted with the mini-pump containing saline (wild type [WT-S], mdx-S). Following completion of drug treatment, animals were sacrificed by cervical dislocation and skeletal muscles (tibialis anterior TA, diaphragm DIA, gastrocnemius Gastro, and Soleus) were harvested. For analysis of biochemistry, skeletal muscles were snap frozen in liquid nitrogen. For preparation of paraffin sections skeletal muscles were fixed in formalin.
- sections were incubated with primary antibody overnight at 4 0 C then incubated in biotinylated secondary antibody for 30 mins at RT, followed by incubation in FITC-streptoavidin conjugated secondary antibody (Molecular Probes) for 1 h at RT. Sections were then washed and mounted using fluorescence mounting medium (DAKO).
- DAKO fluorescence mounting medium
- H&E Hematoxylin and Eosin
- Muscle sections were rehydrated in xylene followed by descending alcohols (100%, 95%, 80%), incubated in Shandon Instant Hematoxylin (Fisher Scientific) for 3 mins, washed 1 min, incubated in Eosin (Fisher Scientific) for 3 mins and then dehydrated in ascending alcohols followed by incubation in xylene. Stained sections were mounted with permount (Fisher Scientific). Quantification of morphometric parameters was performed on -1000 fibers per muscle.
- PAS Periodic Acid Schiff
- mice were injected intravenously through the dorsal tail vein with 50ul/10g of 1 % Evans Blue Dye (EBD, Sigma) in sterilized phosphate-buffered saline (PBS 7.4). Skeletal muscle was harvested 6-8 hrs post-injection and prepared for immunofluorescence as previously described.
- EBD infiltrated fibers sections were incubated in anti-laminin (Sigma) at 4 0 C overnight and then mounted in fluorescent mounting medium (DAKO).
- lmmunoblot Analysis Muscle samples were homogenized, lyzed and quantified for protein concentration using Brafford Assay. Equal concentrations of protein samples were resolved by 6-8% SDS-PAGE and transferred to nitrocellulose membranes. Primary antibodies against IRS, IRS y941 , IRS 8307 , anti-MHC (clone MF20) were used at a dilution of 1 :500. Rabbit polyclonal antibodies were detected using horseradish peroxidase-conjugated anti-rabbit at dilution of 1 :5000. lmmunoblots were developed using with Supersignal West Pico Chemiluminescence substrate. [00259] Kinase Activity Assay.
- Muscle samples were homogenized and quantified for protein concentration using Brafford Assay. Equal concentrations of protein samples were immunoprecipitated for AKT and GSK3- ⁇ overnight at 4 0 C. Sepharose beads containing the immunoprecipitated AKT or GSK3-b were washed and then incubated in reaction buffer a specific peptide substrate ARKRERTYSFGHHA and RRRPASVPPSPSLSRHSSHQRR, respectively with [ ⁇ - 32 P]-ATP at 37 0 C. After incubation, beads were pelleted and equal amounts of supernatant was spotted on p-81 phosphocellulose paper, washed in phosphoric acid, then washed in acetone and air- dried.
- reaction buffer a specific peptide substrate ARKRERTYSFGHHA and RRRPASVPPSPSLSRHSSHQRR, respectively with [ ⁇ - 32 P]-ATP at 37 0 C. After incubation, beads were pelleted and equal amounts of supernatant was spotted on p-81
- the immunoprecipitated beads were washed twice with modified RIPA lysis buffer and once in kinase buffer: (100 mmol/L MOPS pH 7.2, 125 mmol/L ⁇ -glycerol phosphate, 25 mmol/L EGTA, 5 mmol/L sodium orthovanadate, and 5 mmol/L DTT) for AKT kinase activity and 5O mM Tris/HCL pH 7.5, 0.1 mM EGTA, 0.1 % (by volume) 2-mercoptoethanol, 1 OmM magnesium acetate for the AMPK kinase assay.
- kinase buffer 100 mmol/L MOPS pH 7.2, 125 mmol/L ⁇ -glycerol phosphate, 25 mmol/L EGTA, 5 mmol/L sodium orthovanadate, and 5 mmol/L DTT
- the kinase buffer for GSK-3 ⁇ assay consisted of 25 mmol/L HEPES pH 7.4, 10 mmol/L MgCI 2 , and 1 mmol/L DTT. lmmunoprecipitates were then incubated in the specific kinase buffer supplemented with [ ⁇ - 32 P]ATP and either RPRAATF (including PKA inhibitor peptide from Akt1/PKB ⁇ immunoprecipitation kinase assay; Upstate Biotechnology), YRRAAVPPSPSLSRHSSPHQPS (Upstate, Biotechnology) or SAMS (Upstate, Biotechnology) peptides as target substrates for AKT/SGK, GSK3- ⁇ and AMPK, respectively.
- RPRAATF including PKA inhibitor peptide from Akt1/PKB ⁇ immunoprecipitation kinase assay
- Upstate Biotechnology Upstate Biotechnology
- YRRAAVPPSPSLSRHSSPHQPS Upstate, Biotechnology
- SAMS Upstate, Biotechnology
- AMPK AMP adenosine monophosphate
- MM metformin-treated mdx mice also M-mdx, Met-mdx or mdx-Met, etc
- IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATd . Nature. 400, 581-585.
- Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 51 , 2074-2081. [00303] Musi N, Goodyear LJ. (2006). Insulin resistance and improvements in signal transduction. Endocrine. 29, 73-80. Review.
- Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA., 90, 3710-3714.
- MEF2 responds to multiple calcium regulated signals in the control of skeletal muscle fiber type. EMBO J. 19, 1963-1973.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17904009P | 2009-05-18 | 2009-05-18 | |
US24466909P | 2009-09-22 | 2009-09-22 | |
PCT/CA2010/000734 WO2010132982A1 (fr) | 2009-05-18 | 2010-05-18 | Traitement d'une maladie musculaire caractérisée par une résistance à l'insuline |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2432761A1 true EP2432761A1 (fr) | 2012-03-28 |
EP2432761A4 EP2432761A4 (fr) | 2012-12-12 |
Family
ID=43125689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10777262A Withdrawn EP2432761A4 (fr) | 2009-05-18 | 2010-05-18 | Traitement d'une maladie musculaire caractérisée par une résistance à l'insuline |
Country Status (4)
Country | Link |
---|---|
US (1) | US8993633B2 (fr) |
EP (1) | EP2432761A4 (fr) |
CA (1) | CA2762351A1 (fr) |
WO (1) | WO2010132982A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10295547B2 (en) | 2013-03-14 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | Use and treatment of di-amino acid repeat-containing proteins associated with ALS |
EP2837390A1 (fr) * | 2013-08-15 | 2015-02-18 | Universitäts-Kinderspital beider Basel | Préparation pharmaceutique combinée pour utilisation dans le traitement de troubles neuromusculaires |
US20160051477A1 (en) * | 2014-08-21 | 2016-02-25 | Saji Gopinathan | Method for Administering Metformin |
WO2018051355A1 (fr) * | 2016-09-19 | 2018-03-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Tamoxifène ou tamoxifène en combinaison avec de l'arginine/citrulline destinés à être utilisés dans le traitement de la dystrophie musculaire |
JP6931218B2 (ja) * | 2017-04-12 | 2021-09-01 | 国立大学法人東北大学 | 細胞膜の損傷修復促進剤 |
CA3060250A1 (fr) * | 2017-04-17 | 2018-10-25 | University Of Florida Research Foundation, Incorporated | Regulation de la traduction de la proteine ran par les voies pkr et eif2a-p |
CA3076214A1 (fr) * | 2017-09-26 | 2019-04-04 | University Of Florida Research Foundation, Incorporated | Utilisation de metformine et d'analogues de celle-ci pour reduire les taux de proteine ran lors d'un traitement de troubles neurologiques |
FR3078252B1 (fr) * | 2018-02-28 | 2020-08-14 | Biophytis | Phytoecdysones pour leur utilisation dans la prevention de la perte de force musculaire lors d’une immobilisation |
JP2022540819A (ja) * | 2019-07-10 | 2022-09-20 | ユニバーシティ オブ ワシントン | 非ウイルス性免疫標的化 |
WO2023102111A1 (fr) * | 2021-12-01 | 2023-06-08 | University Of Florida Research Foundation, Incorporated | Inhibiteurs à petites molécules de traduction non-aug (ran) associée à la répétition et polythérapies |
CN115494041B (zh) * | 2022-10-24 | 2024-06-14 | 吉林大学 | 一种通过伊文思蓝染料检测糖原的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009112439A1 (fr) * | 2008-03-10 | 2009-09-17 | Janssen Pharmaceutica Nv | 4-aryl-2-anilino-pyrimidines comme inhibiteurs de plk kinases |
WO2010080581A2 (fr) * | 2008-12-19 | 2010-07-15 | The Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Acide valproïque, dérivés, analogues, et compositions les comprenant ainsi que procédés d'utilisation thérapeutique correspondants |
WO2011121109A1 (fr) * | 2010-04-02 | 2011-10-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions comprenant un activateur (metformine/troglitazone) d'ampk pour le traitement d'une dystrophie myotonique de type 1 (dm1) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB607720A (en) * | 1945-12-31 | 1948-09-03 | Arthur Donald Ainley | Manufacture of biguanide derivatives |
US3147271A (en) * | 1960-11-30 | 1964-09-01 | Us Vitamin Pharm Corp | Nu1-pyridylalkyl-n5-substituted biguanides |
BE612641A (fr) | 1961-01-18 | |||
US3366650A (en) * | 1965-10-07 | 1968-01-30 | Squibb & Sons Inc | Tetra-and penta-fluoro-phenyl- and phenylalkyl-biguanides and salts thereof |
US3531484A (en) | 1968-02-14 | 1970-09-29 | Merck & Co Inc | 1-(3-aminopyrazinoyl)-4,5,5-trisubstituted biguanide products |
JP3415643B2 (ja) * | 1992-12-04 | 2003-06-09 | 株式会社ミノファーゲン製薬 | 筋ジストロフィー症治療薬 |
CN101495183A (zh) * | 2006-05-24 | 2009-07-29 | 帝斯曼知识产权资产管理有限公司 | 治疗肌肉障碍和改善肌肉功能 |
-
2010
- 2010-05-18 EP EP10777262A patent/EP2432761A4/fr not_active Withdrawn
- 2010-05-18 US US13/320,906 patent/US8993633B2/en not_active Expired - Fee Related
- 2010-05-18 WO PCT/CA2010/000734 patent/WO2010132982A1/fr active Application Filing
- 2010-05-18 CA CA2762351A patent/CA2762351A1/fr not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009112439A1 (fr) * | 2008-03-10 | 2009-09-17 | Janssen Pharmaceutica Nv | 4-aryl-2-anilino-pyrimidines comme inhibiteurs de plk kinases |
WO2010080581A2 (fr) * | 2008-12-19 | 2010-07-15 | The Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Acide valproïque, dérivés, analogues, et compositions les comprenant ainsi que procédés d'utilisation thérapeutique correspondants |
WO2011121109A1 (fr) * | 2010-04-02 | 2011-10-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions comprenant un activateur (metformine/troglitazone) d'ampk pour le traitement d'une dystrophie myotonique de type 1 (dm1) |
Non-Patent Citations (2)
Title |
---|
KASHIWAGI KEN-ICHIRO ET AL: "Troglitazone not only reduced insulin resistance but also improved myotonia in a patient with myotonic dystrophy", BIOSIS,, 1 April 1999 (1999-04-01), XP002594594, * |
See also references of WO2010132982A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010132982A1 (fr) | 2010-11-25 |
EP2432761A4 (fr) | 2012-12-12 |
US20120065176A1 (en) | 2012-03-15 |
US8993633B2 (en) | 2015-03-31 |
CA2762351A1 (fr) | 2010-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8993633B2 (en) | Treatment of muscle disease characterized by insulin resistance | |
JP5878937B2 (ja) | 代謝障害を処置するための組成物および方法 | |
TWI486338B (zh) | 用以預防及治療涉及ryr受體調節失調症之藥劑 | |
UA71971C2 (en) | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases | |
US20140011782A1 (en) | Drug combinations for the treatment of duchenne muscular dystrophy | |
EP3621610A1 (fr) | Agonistes du récepteur de la sphingosine-1-phosphate utilisés dans la neuroprotection | |
US9439877B2 (en) | Small molecule inhibitors of Dusp6 and uses therefor | |
US7417058B2 (en) | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | |
US9212179B2 (en) | Compositions and methods for the treatment of metabolic disorders | |
EA031503B1 (ru) | Модуляторы сфингозин-1-фосфатного рецептора для лечения сердечно-легочных расстройств | |
WO2018053373A1 (fr) | Utilisations d'inhibiteurs de kinase inductible par un sel (sik) pour traiter l'ostéoporose | |
CA3214155A1 (fr) | Procedes d'inhibition de ras | |
JP2011507850A (ja) | Rhoキナーゼインヒビターとしてのアニリドおよびアナログ | |
BRPI0715620A2 (pt) | inibidores de asmase | |
US20090169540A1 (en) | Use Of An Antagonist Of Epac For Treating Human Cardiac Hypertrophy | |
US20180291013A1 (en) | Compositions and methods for the treatment of metabolic and related disorders | |
BRPI0912545A2 (pt) | Novos moduladores de receptores de esfingosina fosfato | |
Hur et al. | A benzo [b] thiophene-based selective type 4 S1P receptor agonist | |
KR101438532B1 (ko) | 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 및 이의 스크리닝 방법 | |
Lang et al. | Altered activity of signaling pathways in diaphragm and tibialis anterior muscle of dystrophic mice | |
CN109563056B (zh) | 用于调控胞内钙稳态的三唑 | |
US20070129313A1 (en) | Sulfonylamino-peptidomimetics active on the somatostatin receptor subtypes 4 (sstr4) and 1 (sstr1) | |
US9403803B2 (en) | Indole-3-carboxamides as kinase inhibitors | |
US11938198B2 (en) | Treatment of heart disease by disruption of the anchoring of PP2A | |
Liu et al. | Molecular basis of muscle disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20111212 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20121113 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 21/00 20060101ALI20121107BHEP Ipc: A61K 31/155 20060101AFI20121107BHEP |
|
17Q | First examination report despatched |
Effective date: 20131028 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170303 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MEGENEY, LYNN Inventor name: EVANS, CAROL Inventor name: SLASSI, ABDELMALIK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170714 |